Badania Kliniczne
Baza Danych Organizacji DiCE
Patients undergoing treatment often ask about the possibility of enrolling in a clinical trial. A clinical trial is a scientific study. It tests new molecules in the hope that they are safe and more effective than current treatments.
This database is based on clinicaltrials.gov – a global clinical trials database of all diseases and all molecules in development worldwide. It is a shortened version of this, focusing on current clinical trials related to digestive cancers in Europe. The information is updated daily.
Important to remember: please always discuss with your treating physicians first your considerations of partaking in a clinical trial. They are the best judges of its benefits to your particular case.
| NCT ID | Name | Study type | Phase | Status | Country | Disease type | More infos |
|---|---|---|---|---|---|---|---|
| NCT00002692 | Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00002692 | Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver | Interventional | Phase 3 | Unknown status | United Kingdom | Metastatic Cancer | Infos |
| NCT00002793 | Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer | Interventional | Phase 3 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00002793 | Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer | Interventional | Phase 3 | Unknown status | Germany | Metastatic Cancer | Infos |
| NCT00002893 | Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00002896 | Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer | Interventional | Phase 3 | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT00003063 | Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer | Interventional | Phase 3 | Unknown status | Greece | Colorectal Cancer | Infos |
| NCT00003063 | Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer | Interventional | Phase 3 | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT00003260 | Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00003617 | Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach | Interventional | Phase 3 | Unknown status | Poland | Gastric Cancer | Infos |
| NCT00003617 | Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach | Interventional | Phase 3 | Unknown status | Switzerland | Gastric Cancer | Infos |
| NCT00003617 | Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach | Interventional | Phase 3 | Unknown status | United Kingdom | Gastric Cancer | Infos |
| NCT00004115 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy | Interventional | Phase 3 | Unknown status | United Kingdom | Ovarian Cancer | Infos |
| NCT00004115 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy | Interventional | Phase 3 | Unknown status | United Kingdom | Primary Peritoneal Cavity Cancer | Infos |
| NCT00004236 | Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Gastric Cancer | Infos |
| NCT00006112 | Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer | Interventional | Phase 2 | Unknown status | France | Carcinoma of the Appendix | Infos |
| NCT00006112 | Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00006112 | Fluorouracil With or Without Mitomycin in Treating Patients With Peritoneal Cancer | Interventional | Phase 2 | Unknown status | France | Primary Peritoneal Cavity Cancer | Infos |
| NCT00006115 | Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00006117 | Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Belgium | Pancreatic Cancer | Infos |
| NCT00006117 | Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00006468 | Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Austria | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Austria | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Belgium | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | France | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Germany | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Italy | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Netherlands | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Norway | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Norway | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Portugal | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Portugal | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Sweden | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | Sweden | Metastatic Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00006479 | Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Metastatic Cancer | Infos |
| NCT00007826 | Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00010062 | Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer | Interventional | Phase 2 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00010062 | Fluorouracil Plus Radiation Therapy Following Surgery in Treating Patients With Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Luxembourg | Pancreatic Cancer | Infos |
| NCT00010088 | Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct | Interventional | Phase 2 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00010088 | Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct | Interventional | Phase 2 | Unknown status | Luxembourg | Pancreatic Cancer | Infos |
| NCT00010270 | LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer | Interventional | Phase 1 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00010270 | LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer | Interventional | Phase 1 | Unknown status | Germany | Gastric Cancer | Infos |
| NCT00010270 | LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer | Interventional | Phase 1 | Unknown status | Germany | Pancreatic Cancer | Infos |
| NCT00024375 | DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Germany | Pancreatic Cancer | Infos |
| NCT00024375 | DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Netherlands | Pancreatic Cancer | Infos |
| NCT00024375 | DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Pancreatic Cancer | Infos |
| NCT00033319 | Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps | Interventional | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Germany | Fallopian Tube Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Germany | Ovarian Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Germany | Primary Peritoneal Cavity Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Hungary | Fallopian Tube Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Hungary | Ovarian Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Hungary | Primary Peritoneal Cavity Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Netherlands | Fallopian Tube Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Netherlands | Ovarian Cancer | Infos |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Netherlands | Primary Peritoneal Cavity Cancer | Infos |
| NCT00046995 | Combination Chemotherapy in Treating Patients With Colon Cancer | Interventional | Phase 3 | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT00070005 | J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma | Interventional | Phase 3 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT00070213 | Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00072553 | Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00075452 | Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma | Interventional | Phase 3 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00075465 | Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach | Interventional | Phase 2 | Unknown status | France | Gastric Cancer | Infos |
| NCT00075556 | Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00075595 | Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00077389 | Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma | Interventional | Phase 2 | Unknown status | France | Liver Cancer | Infos |
| NCT00077389 | Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma | Interventional | Phase 2 | Unknown status | Ireland | Liver Cancer | Infos |
| NCT00077389 | Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma | Interventional | Phase 2 | Unknown status | Netherlands | Liver Cancer | Infos |
| NCT00077389 | Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma | Interventional | Phase 2 | Unknown status | United Kingdom | Liver Cancer | Infos |
| NCT00079027 | Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | Interventional | Phase 3 | Unknown status | United Kingdom | Liver Cancer | Infos |
| NCT00091312 | Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00091312 | Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Interventional | Phase 3 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00091312 | Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Interventional | Phase 3 | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT00091312 | Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Interventional | Phase 3 | Unknown status | Portugal | Colorectal Cancer | Infos |
| NCT00091312 | Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | Interventional | Phase 3 | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT00108875 | Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Germany | Colon Cancer | Infos |
| NCT00108875 | Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Germany | Pancreatic Cancer | Infos |
| NCT00114829 | Preoperative Assessment of Colon Tumor | Interventional | Phase 4 | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT00119912 | NORCCAP: Norwegian Colorectal Cancer Prevention Trial | Interventional | N/A | Active but recruitment closed | Norway | Adenoma | Infos |
| NCT00119912 | NORCCAP: Norwegian Colorectal Cancer Prevention Trial | Interventional | N/A | Active but recruitment closed | Norway | Colorectal Cancer | Infos |
| NCT00121914 | Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone | Interventional | Phase 3 | Unknown status | Austria | Carcinoma, Hepatocellular | Infos |
| NCT00134758 | Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients | Interventional | Phase 2/Phase 3 | Unknown status | France | Adenomatous Polyposis Coli, Familial | Infos |
| NCT00141466 | Implementation of a New Strategy to Identify HNPCC Patients | Interventional | N/A | Unknown status | Netherlands | Hereditary Nonpolyposis Colorectal Cancer | Infos |
| NCT00162669 | Bevacizumab in Advanced Hepatocellular Carcinoma | Interventional | Phase 2 | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT00182715 | Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | Ireland | Colorectal Cancer | Infos |
| NCT00182715 | Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00188110 | Performance of the Water-Enema Computed Tomography (WE-CT) | Interventional | N/A | Unknown status | France | Colon Cancer | Infos |
| NCT00189683 | Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00197873 | Lactobacillus Rhamnosus in Prevention of Chemotherapy-related Diarrhoea | Interventional | N/A | Unknown status | Finland | Colorectal Cancer | Infos |
| NCT00215722 | XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | Portugal | Colorectal Carcinoma | Infos |
| NCT00220077 | Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Sensitivity in Patients With Operable, Locally Advanced and Metastatic Oesophageal Cancer | Interventional | N/A | Unknown status | United Kingdom | Oesophageal Cancer | Infos |
| NCT00220246 | Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal Cancer | Observational | N/A | Unknown status | Netherlands | Colorectal Neoplasms | Infos |
| NCT00225641 | Assessment of Frequency of Surveillance After Curative Resection in Patients With Stage II and III Colorectal Cancer | Interventional | N/A | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT00250328 | Evaluation of NiTi Laparoscopic Compression Anastomosis Clip (LapCAC) Device for Intra-Corporeal Lap-Colectomy | Interventional | Phase 1 | Unknown status | Israel | Colon Cancer | Infos |
| NCT00253812 | Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy | Interventional | N/A | Unknown status | United Kingdom | Familial Adenomatous Polyposis | Infos |
| NCT00259532 | Three New Methods for Diagnosing Pancreas Cancer | Interventional | N/A | Unknown status | Denmark | Pancreas Cancer | Infos |
| NCT00268411 | Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer | Interventional | Phase 3 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00274872 | Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | Interventional | Phase 2/Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00274885 | Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer | Interventional | Phase 4 | Unknown status | France | Cancer | Infos |
| NCT00275119 | Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | Interventional | Phase 2 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00276705 | Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer | Interventional | Phase 2 | Unknown status | Ireland | Liver Cancer | Infos |
| NCT00276705 | Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Liver Cancer | Infos |
| NCT00287976 | Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma | Interventional | Phase 2 | Unknown status | Ireland | Liver Cancer | Infos |
| NCT00287976 | Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma | Interventional | Phase 2 | Unknown status | Netherlands | Liver Cancer | Infos |
| NCT00287976 | Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma | Interventional | Phase 2 | Unknown status | United Kingdom | Liver Cancer | Infos |
| NCT00299299 | Modelling Internal Hepatic Movement With an External Abdominal Marker | Observational | N/A | Unknown status | United Kingdom | Patients With Liver Metastases From Colorectal Cancer | Infos |
| NCT00303745 | Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00305838 | CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | Interventional | Phase 2 | Unknown status | United Kingdom | Fallopian Tube Cancer | Infos |
| NCT00305838 | CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | Interventional | Phase 2 | Unknown status | United Kingdom | Ovarian Cancer | Infos |
| NCT00305838 | CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | Interventional | Phase 2 | Unknown status | United Kingdom | Primary Peritoneal Cavity Cancer | Infos |
| NCT00319007 | Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis | Interventional | Phase 2 | Unknown status | Netherlands | Adenomatous Polyposis Coli | Infos |
| NCT00346281 | 32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Pancreatic Cancer | Infos |
| NCT00356161 | HAI Via Interventionally Implanted Port Catheter Systems | Interventional | Phase 2 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00356161 | HAI Via Interventionally Implanted Port Catheter Systems | Interventional | Phase 2 | Unknown status | Germany | Hepatocellular Carcinoma | Infos |
| NCT00374660 | Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors | Interventional | Phase 1/Phase 2 | Unknown status | France | Liver Cancer | Infos |
| NCT00383695 | Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer | Interventional | Phase 2 | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT00383695 | Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer | Interventional | Phase 2 | Unknown status | Sweden | Colorectal Cancer | Infos |
| NCT00383695 | Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00389870 | Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00392470 | Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer | Interventional | Phase 1 | Unknown status | Switzerland | Colorectal Cancer | Infos |
| NCT00407186 | Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Gastric Cancer | Infos |
| NCT00411112 | Sentinel Node in Colon Cancer | Interventional | N/A | Unknown status | France | Colon Cancer | Infos |
| NCT00420394 | Perioperative Chemoradiotherapy for Potentially Resectable Gastric Cancer | Interventional | Phase 2 | Unknown status | Israel | Stomach Neoplasms | Infos |
| NCT00433927 | 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) | Interventional | Phase 3 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT00433927 | 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) | Interventional | Phase 3 | Unknown status | Germany | Neoplasm Metastasis | Infos |
| NCT00435097 | Computer Assisted Early Detection of Liver Metastases From fMRI Maps | Observational | N/A | Unknown status | Israel | Metastatic Colorectal Cancer | Infos |
| NCT00438737 | Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00438737 | Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Metastatic Cancer | Infos |
| NCT00440167 | Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine | Interventional | Phase 3 | Unknown status | Germany | Pancreatic Cancer | Infos |
| NCT00442637 | Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma | Interventional | Phase 3 | Unknown status | Netherlands | Colorectal Cancer Metastatic | Infos |
| NCT00450203 | Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer | Interventional | Phase 2/Phase 3 | Unknown status | United Kingdom | Oesophagogastric Cancer | Infos |
| NCT00468416 | Evaluation of NiTi Shape Memory End-to-End Compression Anastomosis Ring (CAR) for Compression Anastomosis in Anterior Resection | Interventional | Phase 2 | Unknown status | Israel | Colorectal Cancer | Infos |
| NCT00474734 | Intravascular Ultrasound for Hepatocellular Carcinoma Staging | Observational | N/A | Unknown status | Switzerland | Hepatocellular Carcinoma | Infos |
| NCT00478946 | A Study of Picoplatin in Colorectal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Russian Federation | Colorectal Cancer | Infos |
| NCT00482222 | Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00482222 | Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Metastatic Cancer | Infos |
| NCT00486460 | Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer | Interventional | Phase 3 | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT00501176 | Preoperative Stent Study | Interventional | N/A | Unknown status | Sweden | Pancreas Cancer | Infos |
| NCT00513266 | Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery | Interventional | Phase 2 | Unknown status | Switzerland | Colorectal Cancer | Infos |
| NCT00513266 | Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery | Interventional | Phase 2 | Unknown status | Switzerland | Metastatic Cancer | Infos |
| NCT00514930 | Multicentre Prospective Clinical Trial for RFA Tumour Aspirator Treatment of Primary and Secondary Malignancies of the Liver | Interventional | Phase 1/Phase 2 | Unknown status | Greece | Liver Cancer | Infos |
| NCT00541021 | Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 3 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00544011 | Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00551057 | Expression of Inflammatory Proteins in Pancreatic Cancer | Observational | N/A | Unknown status | Switzerland | Pancreatic Neoplasms | Infos |
| NCT00559858 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Breast Cancer | Infos |
| NCT00559858 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00559858 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Palmar-plantar Erythrodysesthesia | Infos |
| NCT00560365 | Follow-Up Study of Patients Who Have Undergone Surgery for Stage I, Stage II, or Stage III Colorectal Cancer | Observational | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00582257 | Early Onset and Familial Gastric Cancer Registry | Observational | N/A | Active but recruitment closed | Israel | Gastric Cancer | Infos |
| NCT00628368 | Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer | Interventional | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT00647530 | Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | United Kingdom | Colorectal Cancer | Infos |
| NCT00669370 | Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer | Interventional | Phase 2 | Unknown status | Finland | Stomach Neoplasms | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Estonia | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Hungary | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Israel | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Italy | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Poland | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Turkey | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | Interventional | Phase 3 | Active but recruitment closed | Ukraine | Neoplasms, Gastrointestinal Tract | Infos |
| NCT00690300 | Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Germany | Pancreas Neoplasms | Infos |
| NCT00693290 | Improving Outcomes for Patients Requiring Oral Bowel Preparation for Colonoscopy | Interventional | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00710632 | Screening to Predict Weight Loss in Patients With Cancer | Interventional | N/A | Unknown status | United Kingdom | Gastrointestinal Cancer | Infos |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Israel | Colorectal Cancer | Infos |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | Interventional | Phase 1/Phase 2 | Recruitment open | Israel | Gastric Cancer | Infos |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | Interventional | Phase 4 | Active but recruitment closed | Finland | Gastrointestinal Stromal Tumors | Infos |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | Interventional | Phase 4 | Active but recruitment closed | France | Gastrointestinal Stromal Tumors | Infos |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | Interventional | Phase 4 | Active but recruitment closed | Germany | Gastrointestinal Stromal Tumors | Infos |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | Interventional | Phase 4 | Active but recruitment closed | Italy | Gastrointestinal Stromal Tumors | Infos |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | Interventional | Phase 4 | Active but recruitment closed | Spain | Gastrointestinal Stromal Tumors | Infos |
| NCT00757614 | Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom | Observational | N/A | Unknown status | United Kingdom | Pancreatic Cancer | Infos |
| NCT00757965 | Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom | Observational | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00758381 | Metastatic Advanced Pancreas Sorafenib | Interventional | Phase 2 | Unknown status | Italy | Locally Advanced Pancreatic Cancer | Infos |
| NCT00777478 | Capiri-sutent Phase-1 in Advanced Colo-rectal Cancer | Interventional | Phase 1 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT00777504 | Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | Interventional | Phase 4 | Unknown status | Netherlands | Gastrointestinal Stromal Tumor | Infos |
| NCT00790140 | Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery | Interventional | Phase 4 | Unknown status | Ireland | Esophageal Cancer | Infos |
| NCT00797251 | Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression | Observational | N/A | Unknown status | Italy | Hepatocellular Carcinoma | Infos |
| NCT00797485 | Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | Interventional | Phase 3 | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT00813696 | Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer | Interventional | Phase 3 | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | France | Anxiety Disorder | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | France | Cognitive/Functional Effects | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | France | Colorectal Cancer | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | France | Depression | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | France | Excercise | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | France | Fatigue | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | France | Psychosocial Effects of Cancer and Its Treatment | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | France | Sleep Disorders | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | United Kingdom | Anxiety Disorder | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | United Kingdom | Cognitive/Functional Effects | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | United Kingdom | Colorectal Cancer | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | United Kingdom | Depression | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | United Kingdom | Excercise | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | United Kingdom | Fatigue | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | United Kingdom | Psychosocial Effects of Cancer and Its Treatment | Infos |
| NCT00819208 | Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer | Interventional | N/A | Recruitment open | United Kingdom | Sleep Disorders | Infos |
| NCT00825110 | SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer | Observational | N/A | Recruitment open | United Kingdom | Colorectal Cancer | Infos |
| NCT00838656 | Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Fallopian Tube Cancer | Infos |
| NCT00838656 | Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Ovarian Cancer | Infos |
| NCT00838656 | Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Primary Peritoneal Cavity Cancer | Infos |
| NCT00845884 | Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Israel | Advanced Gastric Cancer | Infos |
| NCT00848952 | Performance of Imaging for the Diagnosis of Small Hepatocellular Carcinoma (< 3 cm)on Cirrhosis | Interventional | N/A | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Belgium | Hepatic Lesions | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Belgium | Liver Metastases | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Belgium | Metastatic Colorectal Cancer | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | France | Hepatic Lesions | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | France | Liver Metastases | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | France | Metastatic Colorectal Cancer | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Italy | Hepatic Lesions | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Italy | Liver Metastases | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Portugal | Hepatic Lesions | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Portugal | Liver Metastases | Infos |
| NCT00852228 | Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy | Interventional | Phase 2 | Unknown status | Portugal | Metastatic Colorectal Cancer | Infos |
| NCT00860691 | Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon Cancer | Interventional | N/A | Unknown status | Croatia | Colonic Neoplasms | Infos |
| NCT00865982 | Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer | Interventional | Phase 2 | Unknown status | Germany | Gastric Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Iceland | Colorectal Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Latvia | Colorectal Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Colorectal Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Norway | Colorectal Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | Colorectal Cancer | Infos |
| NCT00883792 | The Northern-European Initiative on Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Sweden | Colorectal Cancer | Infos |
| NCT00884767 | Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin | Interventional | Phase 2 | Unknown status | France | Chemotherapeutic Agent Toxicity | Infos |
| NCT00884767 | Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin | Interventional | Phase 2 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00884767 | Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin | Interventional | Phase 2 | Unknown status | France | Neurotoxicity | Infos |
| NCT00888797 | β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence | Interventional | Phase 3 | Unknown status | Israel | Colorectal Neoplasms | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Austria | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Denmark | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | France | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Germany | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Netherlands | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Spain | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Sweden | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | Switzerland | Colon Cancer | Infos |
| NCT00903565 | A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint | Observational | N/A | Unknown status | United Kingdom | Colon Cancer | Infos |
| NCT00906997 | Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy | Interventional | Phase 3 | Active but recruitment closed | Spain | Colorectal Cancer | Infos |
| NCT00906997 | Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy | Interventional | Phase 3 | Active but recruitment closed | Spain | Colorectal Neoplasm | Infos |
| NCT00910819 | Tumour Registry Colorectal Cancer | Observational | N/A | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT00931840 | A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma | Interventional | Phase 2 | Unknown status | Israel | Metastatic Colorectal Cancer | Infos |
| NCT00931840 | A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma | Interventional | Phase 2 | Unknown status | Netherlands | Metastatic Colorectal Cancer | Infos |
| NCT00931840 | A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma | Interventional | Phase 2 | Unknown status | United Kingdom | Metastatic Colorectal Cancer | Infos |
| NCT00934505 | Predictive Value of Pet Scan With Fdg Performed During Irradiation in Patients Treated for Oesaphagus Carcinoma | Observational | N/A | Unknown status | France | Oesophageal Cancer | Infos |
| NCT00947102 | Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer | Observational | N/A | Unknown status | Slovenia | Pancreatic Tubular Adenocarcinoma | Infos |
| NCT00958737 | Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer | Infos |
| NCT00963092 | Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer | Observational | N/A | Unknown status | United Kingdom | Gastric Cancer | Infos |
| NCT00963352 | Colon Cancer Prognosis After Radical Surgery | Observational | N/A | Unknown status | Norway | Colon Cancer | Infos |
| NCT00964171 | Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | France | Pancreatic Cancer | Infos |
| NCT00964457 | Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients | Interventional | Phase 2 | Unknown status | Denmark | Rectum Cancer | Infos |
| NCT00973869 | Curcumin in Preventing Colorectal Cancer in Patients Undergoing Colorectal Endoscopy or Colorectal Surgery | Interventional | Phase 1 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT00984048 | Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer | Observational | N/A | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT00994864 | Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer | Interventional | N/A | Active but recruitment closed | Belgium | Colon Cancer | Infos |
| NCT00995202 | Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Belgium | Colorectal Cancer | Infos |
| NCT00995202 | Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Belgium | Pancreatic Acinar Cell Carcinoma | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Belgium | Pancreatic Ductal Adenocarcinoma | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Belgium | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Belgium | Stage IA Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Belgium | Stage IB Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Belgium | Stage IIA Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Belgium | Stage IIB Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Belgium | Stage II Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Belgium | Stage I Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Israel | Pancreatic Acinar Cell Carcinoma | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Israel | Pancreatic Ductal Adenocarcinoma | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Israel | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Israel | Stage IA Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Israel | Stage IB Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Israel | Stage IIA Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Israel | Stage IIB Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Israel | Stage II Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01013649 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | Interventional | Phase 3 | Active but recruitment closed | Israel | Stage I Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01027221 | Low Dose Radiation to Improve T-Cell Infiltration in Pancreatic Cancer | Interventional | N/A | Unknown status | Germany | Primarily Resectable Pancreatic Cancer | Infos |
| NCT01037049 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | Interventional | Phase 2 | Unknown status | Cyprus | Digestive System Neoplasms | Infos |
| NCT01037049 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | Interventional | Phase 2 | Unknown status | United Kingdom | Digestive System Neoplasms | Infos |
| NCT01038154 | Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer | Interventional | Phase 4 | Unknown status | Spain | Esophageal Cancer | Infos |
| NCT01038154 | Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer | Interventional | Phase 4 | Unknown status | Spain | Stomach Cancer | Infos |
| NCT01048216 | Partial Liver Radiotherapy for Unresectable Liver Metastases | Interventional | N/A | Unknown status | United Kingdom | Metastatic Colorectal Liver Cancer | Infos |
| NCT01056796 | Compression Anastomosis For Low Anterior Resection in Previously Radiated Patients Using the CAR™ 27 | Interventional | Phase 2 | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT01062334 | Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection for Rectum Cancer | Interventional | N/A | Unknown status | Denmark | Cancer | Infos |
| NCT01064375 | Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Sweden | Colorectal Cancer | Infos |
| NCT01067053 | Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. | Interventional | Phase 2 | Unknown status | Spain | Metastatic Colorectal Cancer | Infos |
| NCT01071824 | Comparison of Limb Size of Transverse Coloplasty Pouch | Interventional | N/A | Recruitment open | Switzerland | Colon Cancer | Infos |
| NCT01087268 | Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer | Interventional | Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01097265 | Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery | Interventional | Phase 2/Phase 3 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT01106261 | A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer | Interventional | N/A | Active but recruitment closed | Italy | Colorectal Cancer | Infos |
| NCT01106261 | A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer | Interventional | N/A | Active but recruitment closed | Italy | Pulmonary Metastases | Infos |
| NCT01106261 | A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer | Interventional | N/A | Active but recruitment closed | Serbia | Colorectal Cancer | Infos |
| NCT01106261 | A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer | Interventional | N/A | Active but recruitment closed | Serbia | Pulmonary Metastases | Infos |
| NCT01106261 | A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer | Interventional | N/A | Active but recruitment closed | United Kingdom | Colorectal Cancer | Infos |
| NCT01106261 | A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer | Interventional | N/A | Active but recruitment closed | United Kingdom | Pulmonary Metastases | Infos |
| NCT01110785 | Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT01110798 | J-Pouch Colorectal Anastomosis or Straight Colorectal Anastomosis in Treating Patients With Rectal Cancer Who Have Undergone Surgery to Remove the Tumor | Interventional | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT01116804 | Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC) | Interventional | Phase 1 | Unknown status | Belgium | Primary Liver Cancer | Infos |
| NCT01126463 | 188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas | Interventional | Phase 1 | Active but recruitment closed | France | Hepatocellular Carcinomas | Infos |
| NCT01144195 | A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy | Interventional | Phase 2 | Unknown status | Spain | Metastatic Colorectal Cancer | Infos |
| NCT01160419 | Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer | Interventional | Phase 2 | Unknown status | Germany | Gastric Cancer | Infos |
| NCT01167374 | Carbon Ion Radiotherapy for Hepatocellular Carcinoma | Interventional | N/A | Recruitment open | Germany | Hepatocellular Carcinoma | Infos |
| NCT01182246 | AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Sweden | Adenocarcinoma | Infos |
| NCT01182272 | Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery | Interventional | Phase 2 | Unknown status | France | Liver Cancer | Infos |
| NCT01183156 | Re-invitation to Screening Colonoscopy: a Randomized Study | Interventional | N/A | Unknown status | Poland | Colorectal Cancer | Infos |
| NCT01190462 | Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer | Interventional | Phase 2 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT01214681 | Chemoprevention of Colorectal Cancer: the Role of Non-digestible Carbohydrates | Interventional | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01226394 | Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients | Interventional | Phase 3 | Unknown status | France | Colorectal Cancer With a Resected Minimal Synchronous PC | Infos |
| NCT01230697 | Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) | Observational | N/A | Unknown status | Italy | Kidney Cancer | Infos |
| NCT01230697 | Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) | Observational | N/A | Unknown status | Italy | Liver Cancer | Infos |
| NCT01234246 | Sexual Dysfunction and the Quality of Sexual Life in Patients With Colorectal Cancer and Their Partners. | Observational | N/A | Unknown status | Netherlands | Colorectal Cancer Patients and Their Partners | Infos |
| NCT01236989 | Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC | Interventional | N/A | Unknown status | Italy | Patients Affected by Hepatocellular Carcinoma | Infos |
| NCT01249638 | Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC | Interventional | Phase 3 | Unknown status | Germany | Colorectal Cancer Metastatic | Infos |
| NCT01254591 | Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | Interventional | N/A | Unknown status | United Kingdom | Breast Cancer | Infos |
| NCT01254591 | Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | Interventional | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01254591 | Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | Interventional | N/A | Unknown status | United Kingdom | Esophageal Cancer | Infos |
| NCT01254591 | Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | Interventional | N/A | Unknown status | United Kingdom | Head and Neck Cancer | Infos |
| NCT01254591 | Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer | Interventional | N/A | Unknown status | United Kingdom | Lung Cancer | Infos |
| NCT01272557 | Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial | Interventional | Phase 2 | Unknown status | Germany | Liver Carcinoma | Infos |
| NCT01276574 | Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT | Observational | N/A | Active but recruitment closed | Finland | Peritoneal Cancer | Infos |
| NCT01279278 | Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening? | Interventional | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT01279330 | Does the Recall by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening? | Interventional | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT01286064 | Colorectal Cancer Detection by Means of Optical Fluoroscopy | Interventional | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT01292369 | Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study | Observational | N/A | Unknown status | Israel | Breast Cancer | Infos |
| NCT01292369 | Breath Testing for Breast and Colon Cancer Diagnosis- NaNose Study | Observational | N/A | Unknown status | Israel | Colon Cancer | Infos |
| NCT01292681 | Multi-modality Imaging in the Prediction of Response to Systemic Treatment in Colorectal Cancer | Interventional | N/A | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT01300143 | Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma | Interventional | Phase 2 | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT01308086 | Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer | Interventional | Phase 3 | Unknown status | Greece | CRC | Infos |
| NCT01315990 | FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema | Interventional | Phase 4 | Unknown status | Germany | Colorectal Cancer Metastatic | Infos |
| NCT01320319 | Effect of EPA on Aerobic Performance, Muscle, and Quality of Life in Colorectal Cancer Surgery Patients | Interventional | Phase 2/Phase 3 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01322477 | Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency | Observational | N/A | Unknown status | Israel | Hepatocellular Carcinoma | Infos |
| NCT01324076 | Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | Interventional | Phase 3 | Unknown status | United Kingdom | Liver Cancer | Infos |
| NCT01324856 | Pancreaticogastrostomy Versus Pancreaticojejunostomy in Reconstruction After Cephalic Duodenopancreatectomy | Interventional | Phase 1 | Unknown status | Serbia | Pancreatic Cancer | Infos |
| NCT01325961 | Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers | Interventional | N/A | Unknown status | France | Anal Canal Cancers | Infos |
| NCT01325961 | Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers | Interventional | N/A | Unknown status | France | Cervical Cancer | Infos |
| NCT01325961 | Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers | Interventional | N/A | Unknown status | France | Prostate Cancer | Infos |
| NCT01328171 | FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) | Interventional | Phase 2 | Active but recruitment closed | Germany | Metastatic Colorectal Cancer | Infos |
| NCT01330186 | Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy | Observational | N/A | Unknown status | Denmark | Anal Cancer | Infos |
| NCT01345526 | Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream | Interventional | Phase 2 | Unknown status | Germany | Metastatic Colorectal Cancer | Infos |
| NCT01345526 | Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream | Interventional | Phase 2 | Unknown status | Slovenia | Metastatic Colorectal Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Recruitment open | Netherlands | BRAF Mutant Colorectal Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Recruitment open | Netherlands | Pancreatic Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Recruitment open | Spain | BRAF Mutant Colorectal Cancer | Infos |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Interventional | Phase 1 | Recruitment open | Spain | Pancreatic Cancer | Infos |
| NCT01351714 | Safe D3 Right Hemicolectomy for Cancer Through Multidetector Computed Tomography (MDCT) Angio | Interventional | N/A | Recruitment open | Norway | Colon Cancer | Infos |
| NCT01359397 | Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer | Interventional | Phase 2 | Active but recruitment closed | Netherlands | Adenocarcinoma of the Gastro-oesophageal Junction | Infos |
| NCT01359397 | Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer | Interventional | Phase 2 | Active but recruitment closed | Netherlands | Metastatic Gastric Cancer | Infos |
| NCT01363739 | Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab | Observational | N/A | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT01372735 | Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Germany | Pancreatic Neoplasms | Infos |
| NCT01377220 | Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma | Interventional | Phase 2 | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT01380262 | Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment | Observational | N/A | Unknown status | Poland | Colorectal Cancer | Infos |
| NCT01384994 | Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients | Interventional | Phase 2 | Unknown status | Germany | After Resection of Liver Metastases | Infos |
| NCT01384994 | Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients | Interventional | Phase 2 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT01384994 | Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients | Interventional | Phase 2 | Unknown status | Germany | KRAS Wildtype | Infos |
| NCT01387503 | Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging | Interventional | Phase 2/Phase 3 | Unknown status | Italy | Carcinoma, Hepatocellular | Infos |
| NCT01387503 | Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging | Interventional | Phase 2/Phase 3 | Unknown status | Italy | Cirrhosis | Infos |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer | Interventional | Phase 3 | Active but recruitment closed | Austria | Hepatocellular Carcinoma | Infos |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer | Interventional | Phase 3 | Active but recruitment closed | Belgium | Hepatocellular Carcinoma | Infos |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer | Interventional | Phase 3 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer | Interventional | Phase 3 | Active but recruitment closed | Greece | Hepatocellular Carcinoma | Infos |
| NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer | Interventional | Phase 3 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT01394120 | Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Spain | Carcinoma, Pancreatic Ductal | Infos |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Belgium | Fallopian Tube Cancer | Infos |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Belgium | Ovarian Cancer | Infos |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Belgium | Primary Peritoneal Cavity Cancer | Infos |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Fallopian Tube Cancer | Infos |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Ovarian Cancer | Infos |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Primary Peritoneal Cavity Cancer | Infos |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Fallopian Tube Cancer | Infos |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Ovarian Cancer | Infos |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Primary Peritoneal Cavity Cancer | Infos |
| NCT01410760 | PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases | Interventional | Early Phase 1 | Unknown status | United Kingdom | Metastatic Colorectal Cancer | Infos |
| NCT01419860 | Evaluation of Microcirculation in Colon Wall and Bowel Anastomosis by Laser Induced Fluorescence Video Angiography | Interventional | Early Phase 1 | Unknown status | Norway | Colon Cancer | Infos |
| NCT01436656 | A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | Interventional | Phase 1 | Active but recruitment closed | France | Melanoma and Metastatic Colorectal Cancer | Infos |
| NCT01436656 | A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | Interventional | Phase 1 | Active but recruitment closed | Norway | Melanoma and Metastatic Colorectal Cancer | Infos |
| NCT01436656 | A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | Interventional | Phase 1 | Active but recruitment closed | Spain | Melanoma and Metastatic Colorectal Cancer | Infos |
| NCT01436656 | A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | Interventional | Phase 1 | Active but recruitment closed | Switzerland | Melanoma and Metastatic Colorectal Cancer | Infos |
| NCT01441453 | Transient Elastography in Hepatectomy for Hepatocellular Carcinoma | Interventional | N/A | Unknown status | Italy | Hepatocellular Carcinoma | Infos |
| NCT01441453 | Transient Elastography in Hepatectomy for Hepatocellular Carcinoma | Interventional | N/A | Unknown status | Italy | Surgery | Infos |
| NCT01442324 | Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma | Interventional | N/A | Unknown status | Italy | Cholangiocarcinoma | Infos |
| NCT01442324 | Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma | Interventional | N/A | Unknown status | Italy | Metastatic Liver Cancer | Infos |
| NCT01442324 | Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma | Interventional | N/A | Unknown status | Italy | Neoplasm Metastasis | Infos |
| NCT01442935 | Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | Interventional | Phase 2 | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT01444755 | The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric Cancer | Observational | N/A | Unknown status | Turkey | Gastric Cancer | Infos |
| NCT01448655 | Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV) | Observational | N/A | Unknown status | Austria | Colorectal Cancer | Infos |
| NCT01448655 | Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV) | Observational | N/A | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT01448668 | Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV) | Observational | N/A | Unknown status | Austria | Pancreas Cancer | Infos |
| NCT01448668 | Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV) | Observational | N/A | Unknown status | Germany | Pancreas Cancer | Infos |
| NCT01455831 | Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Belgium | Adenocarcinoma of the Colon | Infos |
| NCT01455831 | Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer | Interventional | Phase 3 | Recruitment open | France | Adenocarcinoma of the Colon | Infos |
| NCT01456455 | Gastric Cancer Metastasized to the Central Nervous System (CNS) | Observational | N/A | Unknown status | Switzerland | Gastric Cancer | Infos |
| NCT01458353 | Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer | Interventional | Phase 3 | Unknown status | Spain | Intra-abdominal Abscess | Infos |
| NCT01458353 | Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer | Interventional | Phase 3 | Unknown status | Spain | Peritoneal Contamination After Ileocolonic Anastomosis | Infos |
| NCT01458353 | Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer | Interventional | Phase 3 | Unknown status | Spain | Wound Infection | Infos |
| NCT01464151 | Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study | Observational | N/A | Active but recruitment closed | Netherlands | Colorectal Cancer | Infos |
| NCT01464151 | Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study | Observational | N/A | Active but recruitment closed | Netherlands | Inflammatory Bowel Disease | Infos |
| NCT01470235 | Hypodontia and Ovarian Cancer | Observational | N/A | Unknown status | Denmark | Colon Cancer | Infos |
| NCT01479608 | Liver Transplantation and Colorectal Cancer | Interventional | Phase 2 | Recruitment open | Norway | Colorectal Cancer | Infos |
| NCT01479608 | Liver Transplantation and Colorectal Cancer | Interventional | Phase 2 | Recruitment open | Norway | Liver Metastasis | Infos |
| NCT01492127 | Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment | Interventional | N/A | Unknown status | France | Cirrhosis | Infos |
| NCT01492127 | Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment | Interventional | N/A | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT01509911 | A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment | Interventional | Phase 2 | Unknown status | Israel | Metastatic Pancreatic Cancer | Infos |
| NCT01515787 | PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Israel | Colorectal Cancer | Infos |
| NCT01515787 | PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery | Interventional | Phase 2/Phase 3 | Active but recruitment closed | Switzerland | Colorectal Cancer | Infos |
| NCT01531595 | Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer | Interventional | Phase 2 | Recruitment open | Finland | Metastatic Colorectal Cancer | Infos |
| NCT01531621 | A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland | Observational | N/A | Recruitment open | Finland | Metastatic Colorectal Cancer | Infos |
| NCT01538550 | Pilot Study of a National Screening Programme for Bowel Cancer in Norway | Interventional | N/A | Active but recruitment closed | Norway | Colorectal Cancer | Infos |
| NCT01556490 | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer | Interventional | N/A | Active but recruitment closed | Belgium | Unresectable Hepatocellular Carcinoma | Infos |
| NCT01556490 | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer | Interventional | N/A | Active but recruitment closed | France | Unresectable Hepatocellular Carcinoma | Infos |
| NCT01556490 | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer | Interventional | N/A | Active but recruitment closed | Germany | Unresectable Hepatocellular Carcinoma | Infos |
| NCT01556490 | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer | Interventional | N/A | Active but recruitment closed | Italy | Unresectable Hepatocellular Carcinoma | Infos |
| NCT01556490 | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer | Interventional | N/A | Active but recruitment closed | Netherlands | Unresectable Hepatocellular Carcinoma | Infos |
| NCT01556490 | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer | Interventional | N/A | Active but recruitment closed | Spain | Unresectable Hepatocellular Carcinoma | Infos |
| NCT01556490 | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer | Interventional | N/A | Active but recruitment closed | United Kingdom | Unresectable Hepatocellular Carcinoma | Infos |
| NCT01563133 | Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas | Interventional | N/A | Unknown status | France | Pancreatic Cancer | Infos |
| NCT01570010 | Effect of the New Norwegian Food Based Dietary Guidelines on Chronic Diseases in Colorectal Cancer Survivors | Interventional | N/A | Recruitment open | Norway | Colorectal Cancer | Infos |
| NCT01573468 | Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer | Interventional | Phase 2 | Unknown status | Germany | Gastric Carcinoma | Infos |
| NCT01577511 | Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer | Observational | N/A | Unknown status | France | Colorectal Neoplasms | Infos |
| NCT01585805 | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | Israel | Metastatic Pancreatic Adenocarcinoma | Infos |
| NCT01585805 | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | Israel | Recurrent Pancreatic Carcinoma | Infos |
| NCT01585805 | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | Israel | Stage III Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01585805 | Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | Israel | Stage IV Pancreatic Cancer AJCC v6 and v7 | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | From Surgery in the Two Study Groups. | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | Prophylaxis Given for 8±2 Days After Planned Laparoscopic | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | Safety of Extended 4-week Heparin Prophylaxis Compared to | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | Surgery for Colorectal Cancer. | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | The Clinical Benefit Will be Evaluated as the Difference in | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | the Incidence of VTE or VTE-related Death Occurring Within 30 Days | Infos |
| NCT01589146 | ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. | Interventional | Phase 3 | Unknown status | Italy | The Primary Study Objective is to Assess the Efficacy and | Infos |
| NCT01591590 | Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer | Interventional | N/A | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT01601808 | Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma | Interventional | Phase 2 | Unknown status | United Kingdom | Pancreatic Cancer | Infos |
| NCT01604564 | Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients | Observational | N/A | Active but recruitment closed | Belgium | Adenomatous Polyposis Coli | Infos |
| NCT01604564 | Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients | Observational | N/A | Active but recruitment closed | Belgium | Colitis,Ulcerative | Infos |
| NCT01604564 | Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients | Observational | N/A | Active but recruitment closed | Belgium | Reservoir, Ileoanal | Infos |
| NCT01606098 | The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | Colon Cancer | Infos |
| NCT01606098 | The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | Primary Tumour | Infos |
| NCT01606098 | The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | Rectal Cancer | Infos |
| NCT01606098 | The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Colon Cancer | Infos |
| NCT01606098 | The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Primary Tumour | Infos |
| NCT01606098 | The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Rectal Cancer | Infos |
| NCT01626963 | Single-port Versus Conventional Laparoscopic Colorectal Surgery | Interventional | Phase 1/Phase 2 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01628211 | Second Look Laparoscopy in Colorectal Cancer | Interventional | Phase 2 | Recruitment open | Italy | Colorectal Cancer | Infos |
| NCT01639326 | Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1 | Interventional | Phase 2 | Unknown status | Spain | Metastatic Colorectal Cancer | Infos |
| NCT01641003 | Isolation and Characterization of Cancer Stem Cells Using iFP Technique | Observational | N/A | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT01642875 | Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy | Interventional | Phase 4 | Unknown status | Poland | Pancreatic Cancer | Infos |
| NCT01651013 | Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras | Observational | N/A | Active but recruitment closed | Italy | Metastatic Colorectal Cancer | Infos |
| NCT01651026 | Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal Cancer | Observational | N/A | Recruitment open | Italy | Metastatic Colorectal Cancer | Infos |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Germany | Hepatocellular Carcinoma | Infos |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Hepatocellular Carcinoma | Infos |
| NCT01658878 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT01659502 | Investigator's Initiated Phase II Study for Pancreatic Cancer Patients | Interventional | Phase 2 | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT01662739 | Cremona Population-Based Gastric Tumors Registry | Observational | N/A | Unknown status | Italy | Gastric Cancer | Infos |
| NCT01673607 | Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer | Interventional | Phase 2 | Recruitment open | France | Resectable Hepatic Metastases of Colorectal Cancer | Infos |
| NCT01675258 | Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers | Observational | N/A | Unknown status | Israel | Colorectal Cancer and Pre-cancer Polyps | Infos |
| NCT01675258 | Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers | Observational | N/A | Unknown status | Israel | Gastric Cancer | Infos |
| NCT01675258 | Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers | Observational | N/A | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT01675505 | Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery | Observational | N/A | Unknown status | Greece | Adaptation, Psychological | Infos |
| NCT01675505 | Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery | Observational | N/A | Unknown status | Greece | Functional Insufficiency | Infos |
| NCT01675999 | Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer | Interventional | Phase 2 | Recruitment open | France | Colon Cancer | Infos |
| NCT01675999 | Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer | Interventional | Phase 2 | Recruitment open | France | Locally Advanced Malignant Neoplasm | Infos |
| NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Israel | Pancreatic Ductal Adenocarcinoma | Infos |
| NCT01679756 | INtracorporeal Versus EXTracorpoREal anastoMOsis After Laparoscopic Right Colectomy for Cancer | Interventional | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT01686971 | The Needs of Cancer Survivors | Observational | N/A | Unknown status | Israel | Colon Cancer Patients. | Infos |
| NCT01688232 | The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer | Observational | N/A | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT01688232 | The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer | Observational | N/A | Active but recruitment closed | France | Surgical Resection of the Colorectal Tumor | Infos |
| NCT01704664 | Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients | Interventional | N/A | Recruitment open | Poland | Gastric Cancer | Infos |
| NCT01706809 | Comparing of Different Biomarkers From Vena Rectalis Superior and Vena Cubiti in Patients Undergoing Low Anterior Resection for Rectum Cancer | Observational | N/A | Unknown status | Denmark | Rectal Cancer | Infos |
| NCT01707511 | The Investigation of the EtCO₂- PaCO₂ Relation During Laparoscopic Colon Surgery | Observational | N/A | Unknown status | Turkey | Colorectal Cancer | Infos |
| NCT01713218 | Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer | Interventional | Early Phase 1 | Unknown status | Belgium | Pancreatic Adenocarcinoma Resectable | Infos |
| NCT01715402 | Optimization of Health Expenditure in Liver Surgery | Observational | N/A | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT01717196 | Diagnostic Accuracy of FNA: is Aspiration- Related? | Interventional | N/A | Unknown status | Italy | PANCREATIC CANCER | Infos |
| NCT01717807 | C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR). | Observational | N/A | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT01718873 | Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer | Interventional | Phase 3 | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Belgium | Advanced Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Belgium | Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Cyprus | Advanced Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Cyprus | Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | France | Advanced Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Germany | Advanced Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Greece | Advanced Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Greece | Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Italy | Advanced Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Italy | Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Poland | Advanced Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Poland | Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Portugal | Advanced Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Portugal | Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Spain | Advanced Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Spain | Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Sweden | Advanced Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Sweden | Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Switzerland | Advanced Colorectal Cancer | Infos |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer | Observational | N/A | Active but recruitment closed | Switzerland | Colorectal Cancer | Infos |
| NCT01726010 | 22-G-Procore Needle for the Diagnosis of SETs of the Upper GI Tract | Interventional | N/A | Unknown status | Germany | Subepithelial Tumors of the Upper Gastrointestinal Tract | Infos |
| NCT01726309 | Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 | Observational | N/A | Active but recruitment closed | Ireland | Colorectal Cancer | Infos |
| NCT01726452 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Oesophageal Cancer | Infos |
| NCT01726452 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | Interventional | Phase 3 | Active but recruitment closed | France | Oesophageal Cancer | Infos |
| NCT01726452 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Oesophageal Cancer | Infos |
| NCT01726452 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | Interventional | Phase 3 | Active but recruitment closed | Sweden | Oesophageal Cancer | Infos |
| NCT01726452 | NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Oesophageal Cancer | Infos |
| NCT01729481 | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Germany | Metastatic Pancreatic Adenocarcinoma | Infos |
| NCT01731366 | The Effect of Whole Grain on Gut Microbiome and Metabolic Health | Interventional | N/A | Unknown status | Denmark | Injury of Gastrointestinal Tract | Infos |
| NCT01744509 | PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening Program | Interventional | N/A | Unknown status | Italy | Colon Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Austria | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Belgium | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Denmark | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Estonia | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Germany | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Greece | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Netherlands | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Norway | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Romania | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Russian Federation | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Spain | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | Sweden | Metastatic Colorectal Cancer | Infos |
| NCT01754272 | A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | Observational | N/A | Unknown status | United Kingdom | Metastatic Colorectal Cancer | Infos |
| NCT01761097 | Endocuff Adenoma Detection Rate Pilot Study | Interventional | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Belgium | Hepatocellular Carcinoma (HCC) | Infos |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | France | Hepatocellular Carcinoma (HCC) | Infos |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Germany | Hepatocellular Carcinoma (HCC) | Infos |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Israel | Hepatocellular Carcinoma (HCC) | Infos |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Italy | Hepatocellular Carcinoma (HCC) | Infos |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Poland | Hepatocellular Carcinoma (HCC) | Infos |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Hepatocellular Carcinoma (HCC) | Infos |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Spain | Hepatocellular Carcinoma (HCC) | Infos |
| NCT01761266 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma (HCC) | Infos |
| NCT01762813 | Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer | Observational | N/A | Recruitment open | Norway | Colorectal Cancer | Infos |
| NCT01779583 | Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients ("EXO-PPP Study") | Observational | N/A | Unknown status | Spain | Gastric Cancer | Infos |
| NCT01786122 | Clinical Trial: Effectiveness and Efficiency of Physical Exercise in Cancer Patients | Interventional | N/A | Unknown status | Spain | Digestive System Neoplasms | Infos |
| NCT01786200 | Physiological Effects of Altering Cancer-related Inflammation | Interventional | N/A | Unknown status | United Kingdom | Colon Cancer | Infos |
| NCT01787539 | The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer | Interventional | Phase 2/Phase 3 | Recruitment open | Poland | Gastric Cancer | Infos |
| NCT01792934 | Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases | Interventional | N/A | Unknown status | Netherlands | Multi-organ Metastatic Colorectal Cancer | Infos |
| NCT01795768 | Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours | Interventional | Phase 2 | Unknown status | United Kingdom | Gastric Cancer | Infos |
| NCT01795768 | Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours | Interventional | Phase 2 | Unknown status | United Kingdom | Oesophageal Cancer | Infos |
| NCT01798173 | Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients | Interventional | N/A | Unknown status | France | Cirrhosis With Hepatocellular Carcinoma | Infos |
| NCT01798173 | Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients | Interventional | N/A | Unknown status | France | Cirrhosis Without Hepatocellular Carcinoma | Infos |
| NCT01801904 | A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Italy | Metastatic Colorectal Cancer | Infos |
| NCT01802645 | Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases | Interventional | Phase 2 | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT01814150 | The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel | Observational | N/A | Unknown status | Israel | Metastatic Gastric Cancer | Infos |
| NCT01827553 | Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Germany | Pancreatic Cancer | Infos |
| NCT01843829 | A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer | Interventional | Phase 2 | Unknown status | United Kingdom | Oesophageal Cancer | Infos |
| NCT01845337 | Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Gastrointestinal Cancer | Infos |
| NCT01845337 | Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Pancreatic Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Austria | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Austria | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Austria | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Belgium | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Belgium | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Belgium | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Czechia | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Czechia | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Czechia | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Finland | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Finland | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Finland | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | France | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | France | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | France | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Germany | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Germany | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Germany | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Hungary | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Hungary | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Hungary | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Ireland | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Ireland | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Ireland | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Italy | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Italy | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Italy | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Luxembourg | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Luxembourg | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Luxembourg | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Norway | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Norway | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Norway | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Sweden | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Sweden | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Sweden | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Low-grade Serous Fallopian Tube Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Low-grade Serous Ovarian Cancer | Infos |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Low-grade Serous Peritoneal Cancer | Infos |
| NCT01853059 | Functional Outcomes Following Anal Cancer Treatment | Observational | N/A | Unknown status | United Kingdom | Anal Cancer | Infos |
| NCT01876901 | Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR) | Interventional | Phase 2 | Unknown status | France | Medium and Lower Rectal Cancer | Infos |
| NCT01879878 | Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial] | Interventional | N/A | Unknown status | Germany | Pancreatic Ductal Adenocarcinoma | Infos |
| NCT01885702 | Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Colorectal Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | France | Epithelial Ovarian Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | France | Fallopian Tube Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | France | Ovarian Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | France | Peritoneal Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | Spain | Epithelial Ovarian Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | Spain | Fallopian Tube Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | Spain | Ovarian Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | Spain | Peritoneal Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Epithelial Ovarian Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Fallopian Tube Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Ovarian Cancer | Infos |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Peritoneal Cancer | Infos |
| NCT01891539 | Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma | Observational | N/A | Recruitment open | Italy | Liver Cell Carcinoma Non-resectable | Infos |
| NCT01892527 | Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects | Interventional | Phase 2 | Unknown status | Italy | Colorectal Cancer Metastatic | Infos |
| NCT01895257 | Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer | Interventional | Phase 3 | Unknown status | Belgium | Colorectal Cancer | Infos |
| NCT01898104 | Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | Italy | Colorectal Cancer | Infos |
| NCT01898741 | Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Netherlands | Pancreatic Cancer | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | Belgium | Hepatocellular Carcinoma | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | Georgia | Hepatocellular Carcinoma | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | Germany | Hepatocellular Carcinoma | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | Ireland | Hepatocellular Carcinoma | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Hepatocellular Carcinoma | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | Poland | Hepatocellular Carcinoma | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | Romania | Hepatocellular Carcinoma | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | Spain | Hepatocellular Carcinoma | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | Turkey | Hepatocellular Carcinoma | Infos |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT01910610 | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer | Interventional | Phase 3 | Recruitment open | France | Colorectal Cancer Metastatic | Infos |
| NCT01910610 | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Ireland | Colorectal Cancer Metastatic | Infos |
| NCT01910610 | Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Israel | Colorectal Cancer Metastatic | Infos |
| NCT01918527 | Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer | Interventional | Phase 3 | Recruitment open | Denmark | Colon Cancer | Infos |
| NCT01918527 | Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer | Interventional | Phase 3 | Recruitment open | Norway | Colon Cancer | Infos |
| NCT01918527 | Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer | Interventional | Phase 3 | Recruitment open | Sweden | Colon Cancer | Infos |
| NCT01919151 | Micrometastasis in Gastrointestinal Cancer | Observational | N/A | Unknown status | Norway | Colorectal Cancer | Infos |
| NCT01919151 | Micrometastasis in Gastrointestinal Cancer | Observational | N/A | Unknown status | Norway | Pancreatic Adenocarcinoma | Infos |
| NCT01927328 | Iron Replacement in Oesophagogastric Neoplasia | Interventional | Phase 4 | Unknown status | United Kingdom | Gastric Cancer | Infos |
| NCT01937429 | Effectiveness of Instillation of Blue Water (Indigo Carmin®) for Colonoscopy | Interventional | Phase 3 | Unknown status | France | Adenoma Detection to Prevent Colorectal Cancer | Infos |
| NCT01937780 | Anal Cancer Radiotherapy Study | Observational | N/A | Active but recruitment closed | Norway | Anal Cancer | Infos |
| NCT01939665 | PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma | Interventional | Phase 1/Phase 2 | Unknown status | Netherlands | Pancreatic Cancer | Infos |
| NCT01943786 | RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab | Observational | N/A | Unknown status | Spain | Colorectal Cancer Metastatic | Infos |
| NCT01945723 | Tissue Characterization From Various Parts of the Gastrointestinal Tract in Healthy Volunteers | Observational | N/A | Unknown status | Israel | Healthy | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Austria | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Austria | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Austria | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Austria | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Austria | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Austria | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Austria | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Austria | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Austria | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Austria | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Czechia | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Czechia | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Czechia | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Czechia | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Czechia | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Czechia | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Czechia | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Czechia | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Czechia | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Czechia | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Finland | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Finland | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Finland | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Finland | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Finland | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Finland | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Finland | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Finland | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Finland | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Finland | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | France | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | France | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | France | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | France | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | France | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | France | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | France | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | France | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | France | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | France | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Germany | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Germany | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Germany | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Germany | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Germany | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Germany | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Germany | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Germany | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Germany | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Germany | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Italy | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Italy | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Italy | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Italy | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Italy | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Italy | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Italy | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Italy | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Italy | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Italy | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Portugal | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Portugal | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Portugal | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Portugal | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Portugal | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Portugal | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Portugal | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Portugal | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Portugal | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Portugal | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Spain | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Spain | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Spain | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Spain | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Spain | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Spain | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Spain | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Spain | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Spain | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | Spain | Pancreatic Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Antimetabolites, Antineoplastic | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Digestive System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Digestive System Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Endocrine Gland Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Endocrine System Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Gemcitabine | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Neoplasms | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Neoplasms by Site | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Pancreatic Diseases | Infos |
| NCT01964430 | Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Pancreatic Neoplasms | Infos |
| NCT01964534 | Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer | Interventional | Phase 2 | Unknown status | France | Metastatic Pancreatic Cancer | Infos |
| NCT01966081 | AGARIC Case Control Study | Interventional | N/A | Unknown status | France | First Recently-diagnosed Colorectal Cancer | Infos |
| NCT01968213 | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Interventional | Phase 3 | Active but recruitment closed | Belgium | Peritoneal Cancer | Infos |
| NCT01968213 | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Interventional | Phase 3 | Active but recruitment closed | France | Peritoneal Cancer | Infos |
| NCT01968213 | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Interventional | Phase 3 | Active but recruitment closed | Germany | Peritoneal Cancer | Infos |
| NCT01968213 | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Interventional | Phase 3 | Active but recruitment closed | Israel | Peritoneal Cancer | Infos |
| NCT01968213 | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Interventional | Phase 3 | Active but recruitment closed | Italy | Peritoneal Cancer | Infos |
| NCT01968213 | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Peritoneal Cancer | Infos |
| NCT01968213 | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Peritoneal Cancer | Infos |
| NCT01983098 | Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment | Observational | N/A | Unknown status | France | To Compare the Monitoring of Circulating Tumor DNA With the Efficacy of Chemotherapy Evaluated by Computer Tomography Scan. | Infos |
| NCT01991080 | The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant Chemotherapy | Interventional | N/A | Unknown status | Israel | Colon Cancer | Infos |
| NCT01991873 | Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer | Interventional | Phase 2 | Recruitment open | Germany | Metastatic Colorectal Cancer | Infos |
| NCT01995942 | Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial | Observational | N/A | Active but recruitment closed | United Kingdom | Digestive System Neoplasms | Infos |
| NCT02002195 | Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer | Observational | N/A | Recruitment open | Italy | Metastatic Gastric Cancer | Infos |
| NCT02002299 | Does Surface Tell us About the Invasive Front in Colorectal Cancer | Observational | N/A | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT02005965 | Low Rectal Cancer Study (MERCURY II) | Observational | N/A | Active but recruitment closed | Germany | Digestive System Neoplasms | Infos |
| NCT02005965 | Low Rectal Cancer Study (MERCURY II) | Observational | N/A | Active but recruitment closed | Serbia | Digestive System Neoplasms | Infos |
| NCT02005965 | Low Rectal Cancer Study (MERCURY II) | Observational | N/A | Active but recruitment closed | United Kingdom | Digestive System Neoplasms | Infos |
| NCT02007148 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer | Interventional | Phase 2 | Recruitment open | Italy | Gastric Adenocarcinoma | Infos |
| NCT02007148 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer | Interventional | Phase 2 | Recruitment open | Italy | Gastroesophageal Junction Adenocarcinoma | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Anal Cancer | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Colon Cancer | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Familial Adenomatous Polyposis | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Gastric Cancer | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Liver Cancer | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Lynch Syndrome | Infos |
| NCT02012699 | Integrated Cancer Repository for Cancer Research | Observational | N/A | Recruitment open | Italy | Pancreatic Cancer | Infos |
| NCT02024009 | Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2 | Interventional | Phase 1/Phase 2 | Unknown status | United Kingdom | Pancreatic Neoplasms (Locally Advanced Non-metastatic) | Infos |
| NCT02039336 | Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC | Interventional | Phase 1/Phase 2 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT02045680 | RADOX' Reduced Abdominal Distension and Oxygen Delivery | Observational | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT02047513 | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | Germany | Ductal Adenocarcinoma of the Pancreas | Infos |
| NCT02047513 | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | Germany | Resectable Pancreatic Cancer | Infos |
| NCT02047994 | Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality | Interventional | Phase 4 | Recruitment open | Latvia | Atrophic Gastritis | Infos |
| NCT02047994 | Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality | Interventional | Phase 4 | Recruitment open | Latvia | Gastric Cancer | Infos |
| NCT02047994 | Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality | Interventional | Phase 4 | Recruitment open | Latvia | Helicobacter Pylori Infections | Infos |
| NCT02050737 | Plasma Biomarkers C-RAC, ICORG 12-27, V1 | Observational | N/A | Active but recruitment closed | Ireland | Colorectal Cancer | Infos |
| NCT02051283 | Pretreatment MRI Predicting Outcome After Radio-frequency Ablation of HCC | Observational | N/A | Unknown status | Belgium | Hepatocellular Carcinoma | Infos |
| NCT02051868 | International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel | Interventional | Phase 2 | Unknown status | United Kingdom | Squamous Cell Carcinoma of the Anus | Infos |
| NCT02053805 | Prostate Cancer Screening Among Men With High Risk Genetic Predisposition | Interventional | N/A | Unknown status | Israel | Lynch Syndrome | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Belgium | Microsatellite Stable Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Belgium | Microsatellite Unstable Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Belgium | Mismatch Repair Deficient Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Belgium | Mismatch Repair Proficient Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | France | Microsatellite Stable Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | France | Microsatellite Unstable Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | France | Mismatch Repair Deficient Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | France | Mismatch Repair Proficient Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Ireland | Microsatellite Stable Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Ireland | Microsatellite Unstable Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Ireland | Mismatch Repair Deficient Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Ireland | Mismatch Repair Proficient Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Italy | Microsatellite Stable Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Italy | Microsatellite Unstable Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Italy | Mismatch Repair Deficient Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Italy | Mismatch Repair Proficient Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Spain | Microsatellite Stable Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Spain | Microsatellite Unstable Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Spain | Mismatch Repair Deficient Colorectal Cancer | Infos |
| NCT02060188 | An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread | Interventional | Phase 2 | Active but recruitment closed | Spain | Mismatch Repair Proficient Colorectal Cancer | Infos |
| NCT02066259 | OctavaColon Cancer Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol | Observational | N/A | Unknown status | Israel | Colon Cancer | Infos |
| NCT02070146 | Prospective Data Collection Initiative on Colorectal Cancer | Observational | N/A | Recruitment open | Netherlands | Colorectal Cancer | Infos |
| NCT02075086 | Angiogenic Switch in Patients With Colorectal Cancer | Interventional | Phase 2 | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Active but recruitment closed | Austria | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Active but recruitment closed | Belgium | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Active but recruitment closed | Estonia | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Active but recruitment closed | France | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Active but recruitment closed | Germany | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Active but recruitment closed | Italy | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Active but recruitment closed | Spain | Metastatic Colorectal Cancer | Infos |
| NCT02077868 | Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Metastatic Colorectal Cancer | Infos |
| NCT02078245 | Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer. | Observational | N/A | Recruitment open | Sweden | Hereditary Pancreatic Cancer | Infos |
| NCT02078245 | Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer. | Observational | N/A | Recruitment open | Sweden | Hereditary Pancreatitis | Infos |
| NCT02079363 | DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer | Observational | N/A | Unknown status | Denmark | Pancreatic Diseases | Infos |
| NCT02079363 | DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer | Observational | N/A | Unknown status | Denmark | Pancreatic Neoplasms | Infos |
| NCT02079363 | DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer | Observational | N/A | Unknown status | Denmark | Pancreatitis | Infos |
| NCT02089269 | Tumor Registry Pancreatic Cancer | Observational | N/A | Recruitment open | Germany | Pancreas Cancer | Infos |
| NCT02112357 | Feasibility of a Molecular Characterisation Approach to Treatment | Observational | N/A | Unknown status | United Kingdom | Advanced Gastrointestinal Cancers | Infos |
| NCT02117466 | Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | Netherlands | Metastatic Colorectal Cancer | Infos |
| NCT02125136 | Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | Germany | Ductal Adenocarcinoma of the Pancreas | Infos |
| NCT02125409 | Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action | Interventional | Phase 3 | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | Interventional | Phase 2 | Active but recruitment closed | Bulgaria | Hepatocellular Carcinoma | Infos |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | Interventional | Phase 2 | Active but recruitment closed | Israel | Hepatocellular Carcinoma | Infos |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | Interventional | Phase 2 | Active but recruitment closed | Romania | Hepatocellular Carcinoma | Infos |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | Interventional | Phase 2 | Active but recruitment closed | Serbia | Hepatocellular Carcinoma | Infos |
| NCT02138370 | Comprehensive Immune-landscape in Localized Colorectal Cancer | Observational | N/A | Unknown status | Switzerland | Colorectal Cancer | Infos |
| NCT02138370 | Comprehensive Immune-landscape in Localized Colorectal Cancer | Observational | N/A | Unknown status | Switzerland | Immune Landscape | Infos |
| NCT02143219 | Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | France | Pancreatic Metastatic Cancer | Infos |
| NCT02143219 | Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer | Interventional | Phase 2 | Active but recruitment closed | France | Toxicity | Infos |
| NCT02145013 | Portal Hypertension and Liver Resection in Patients With Hepatocellular Carcinoma | Observational | N/A | Unknown status | France | Primary Liver Cancers | Infos |
| NCT02158988 | Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis | Interventional | Phase 3 | Active but recruitment closed | Germany | Malignant Neoplasm of Stomach | Infos |
| NCT02158988 | Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis | Interventional | Phase 3 | Active but recruitment closed | Germany | Secondary Malignant Neoplasm of Other and Unspecified Sites | Infos |
| NCT02158988 | Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis | Interventional | Phase 3 | Active but recruitment closed | Germany | Secondary Malignant Neoplasm of Peritoneum | Infos |
| NCT02162563 | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases | Interventional | Phase 3 | Recruitment open | Belgium | Colorectal Cancer | Infos |
| NCT02162563 | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases | Interventional | Phase 3 | Recruitment open | Belgium | Liver Metastases | Infos |
| NCT02162563 | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases | Interventional | Phase 3 | Recruitment open | Netherlands | Colorectal Cancer | Infos |
| NCT02162563 | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases | Interventional | Phase 3 | Recruitment open | Netherlands | Liver Metastases | Infos |
| NCT02164149 | Length of Tumour Feeding Artery After Colon Cancer Surgery | Observational | N/A | Unknown status | Denmark | Colon Cancer | Infos |
| NCT02173990 | Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR). | Interventional | Phase 2 | Unknown status | France | Metastatic Colorectal Cancer | Infos |
| NCT02175914 | Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis | Interventional | Phase 4 | Unknown status | Israel | FAP-Familial Adenomatous Polyposis | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Belgium | Germline BRCA1/2 Mutations and | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Belgium | Metastatic Adenocarcinoma of the Pancreas | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | France | Germline BRCA1/2 Mutations and | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | France | Metastatic Adenocarcinoma of the Pancreas | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Germany | Germline BRCA1/2 Mutations and | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Germany | Metastatic Adenocarcinoma of the Pancreas | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Israel | Germline BRCA1/2 Mutations and | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Israel | Metastatic Adenocarcinoma of the Pancreas | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Italy | Germline BRCA1/2 Mutations and | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Italy | Metastatic Adenocarcinoma of the Pancreas | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Germline BRCA1/2 Mutations and | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Metastatic Adenocarcinoma of the Pancreas | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Spain | Germline BRCA1/2 Mutations and | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | Spain | Metastatic Adenocarcinoma of the Pancreas | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Germline BRCA1/2 Mutations and | Infos |
| NCT02184195 | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Metastatic Adenocarcinoma of the Pancreas | Infos |
| NCT02184663 | Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer | Interventional | N/A | Recruitment open | France | Metastatic Pancreatic Cancer | Infos |
| NCT02184663 | Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer | Interventional | N/A | Recruitment open | France | Unresectable Locally Advanced Cancer | Infos |
| NCT02188927 | Effect of an Advanced Notification Letter on Screening Colonoscopy Participation | Interventional | N/A | Unknown status | Poland | Colorectal Cancer | Infos |
| NCT02197351 | Narrow Band Imaging for Gastric Neoplasia | Interventional | N/A | Recruitment open | Portugal | Gastric Cancer | Infos |
| NCT02208804 | Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization | Interventional | Phase 2/Phase 3 | Unknown status | Netherlands | Digestive System Neoplasms | Infos |
| NCT02209415 | EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer | Interventional | N/A | Unknown status | Denmark | Esophageal Cancer | Infos |
| NCT02209415 | EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer | Interventional | N/A | Unknown status | Denmark | Pancreatic Cancer | Infos |
| NCT02209415 | EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer | Interventional | N/A | Unknown status | Denmark | Stomach Cancer | Infos |
| NCT02215577 | ALPPS Versus PVE/PL | Interventional | N/A | Unknown status | Denmark | Colorectal Cancer | Infos |
| NCT02215577 | ALPPS Versus PVE/PL | Interventional | N/A | Unknown status | Norway | Colorectal Cancer | Infos |
| NCT02215577 | ALPPS Versus PVE/PL | Interventional | N/A | Unknown status | Sweden | Colorectal Cancer | Infos |
| NCT02215889 | Partial Liver Segment 2/3 Transplantation Study | Interventional | Phase 1/Phase 2 | Recruitment open | Norway | Colorectal Cancer | Infos |
| NCT02216578 | Ph II CABOGIST in GIST | Interventional | Phase 2 | Active but recruitment closed | Belgium | Metastatic Gastrointestinal Stromal Tumor | Infos |
| NCT02216578 | Ph II CABOGIST in GIST | Interventional | Phase 2 | Active but recruitment closed | Czechia | Metastatic Gastrointestinal Stromal Tumor | Infos |
| NCT02216578 | Ph II CABOGIST in GIST | Interventional | Phase 2 | Active but recruitment closed | France | Metastatic Gastrointestinal Stromal Tumor | Infos |
| NCT02216578 | Ph II CABOGIST in GIST | Interventional | Phase 2 | Active but recruitment closed | Germany | Metastatic Gastrointestinal Stromal Tumor | Infos |
| NCT02216578 | Ph II CABOGIST in GIST | Interventional | Phase 2 | Active but recruitment closed | Hungary | Metastatic Gastrointestinal Stromal Tumor | Infos |
| NCT02216578 | Ph II CABOGIST in GIST | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Metastatic Gastrointestinal Stromal Tumor | Infos |
| NCT02230553 | Lapatinib Plus Trametinib in KRAS Mutant NSCLC | Interventional | Phase 1/Phase 2 | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT02231086 | Adjuvant HIPEC in High Risk Colon Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Colorectal Neoplasms | Infos |
| NCT02231086 | Adjuvant HIPEC in High Risk Colon Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Peritoneal Neoplasms | Infos |
| NCT02231385 | Acetic Acid Colonoscopy Enhancement Study | Interventional | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT02246322 | A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions. | Interventional | N/A | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT02246634 | Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) | Interventional | N/A | Unknown status | United Kingdom | Colorectal Neoplasms | Infos |
| NCT02246634 | Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) | Interventional | N/A | Unknown status | United Kingdom | Hepatic Neoplasms | Infos |
| NCT02246634 | Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) | Interventional | N/A | Unknown status | United Kingdom | Neoplasm Metastases | Infos |
| NCT02246725 | Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial. | Observational | N/A | Recruitment open | Sweden | Tumor in Upper Gastrointestinal Canal or Patients With Colorectal Cancer | Infos |
| NCT02248519 | Laparoscopic Versus Open Gastrectomy for Gastric Cancer | Interventional | N/A | Active but recruitment closed | Netherlands | Gastric Cancer | Infos |
| NCT02254941 | Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer | Observational | N/A | Active but recruitment closed | Spain | Metastatic Colon Cancer | Infos |
| NCT02260128 | Effect of Chewing Gum on Postoperative Bowel Function Following Upper GI Tract Cancer Surgery | Interventional | N/A | Unknown status | Denmark | Pancreatic Cancer | Infos |
| NCT02260505 | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) | Interventional | Phase 3 | Recruitment open | France | Gastrointestinal Stromal Tumors | Infos |
| NCT02260505 | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) | Interventional | Phase 3 | Recruitment open | France | Resected Gastrointestinal Stromal Tumors | Infos |
| NCT02272790 | Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 2 | Active but recruitment closed | Netherlands | Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation | Infos |
| NCT02272790 | Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation | Infos |
| NCT02274753 | Personalizing Colorectal Cancer Medicine (ImmuCol2) | Observational | N/A | Active but recruitment closed | France | Colon Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Belgium | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Bosnia and Herzegovina | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Cyprus | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Denmark | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Greece | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Italy | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Netherlands | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Poland | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Portugal | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Russian Federation | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Serbia | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Slovakia | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Slovenia | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Spain | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Sweden | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | Turkey | Colorectal Cancer | Infos |
| NCT02291289 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Colorectal Cancer | Infos |
| NCT02296203 | Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). | Interventional | Phase 2 | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT02299596 | Physical Activity in Relation to Surgical Procedures | Interventional | N/A | Active but recruitment closed | Sweden | Colorectal Cancer | Infos |
| NCT02300922 | Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer | Interventional | Phase 1/Phase 2 | Unknown status | France | Metastatic Colorectal Cancer | Infos |
| NCT02301286 | A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients | Interventional | Phase 3 | Recruitment open | Netherlands | Adjuvant Therapy | Infos |
| NCT02301286 | A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients | Interventional | Phase 3 | Recruitment open | Netherlands | Colon Cancer | Infos |
| NCT02304978 | Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults | Interventional | Early Phase 1 | Recruitment open | France | Colorectal Cancer | Infos |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy | Interventional | Phase 2 | Active but recruitment closed | Italy | Pancreas Cancer | Infos |
| NCT02308722 | SBRT Pre-operatively for Pancreatic Cancer | Interventional | Phase 1 | Unknown status | United Kingdom | Pancreatic Neoplasms | Infos |
| NCT02325323 | Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal Metaplasia | Observational | N/A | Unknown status | France | Stomach Cancer | Infos |
| NCT02325453 | Robotic, Laparoscopic and Open Surgery for Gastric Cancer Compared on Surgical, Clinical and Oncological Outcomes | Observational | N/A | Recruitment open | Italy | Gastric Cancer | Infos |
| NCT02327494 | Study to Evaluate Oxygen Monitoring at Different Stages of Neuromuscular Blockade in Colorectal Surgery | Observational | N/A | Unknown status | Spain | Colorectal Cancer | Infos |
| NCT02327819 | The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer | Interventional | N/A | Unknown status | Israel | Primary Liver Cancer | Infos |
| NCT02328677 | ColoCare Study - Colorectal Cancer Cohort | Observational | N/A | Recruitment open | Germany | Colorectal Cancer | Infos |
| NCT02331927 | PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Germany | Metastatic Colorectal Cancer | Infos |
| NCT02339116 | Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC | Interventional | Phase 3 | Active but recruitment closed | Italy | Metastatic Colorectal Cancer | Infos |
| NCT02345408 | Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma | Interventional | Phase 1 | Active but recruitment closed | Netherlands | Pancreatic Cancer | Infos |
| NCT02347735 | Predictive Factors for Anastomotic Leakage After Colorectal Surgery | Observational | N/A | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT02352337 | First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem | Interventional | Phase 2 | Active but recruitment closed | France | Metastatic Pancreatic Cancer | Infos |
| NCT02355119 | Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer | Interventional | Phase 3 | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT02356406 | Celiac Plexus Radiosurgery for Pain Management | Interventional | Phase 2 | Unknown status | Israel | Digestive System Neoplasms | Infos |
| NCT02363049 | Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer | Interventional | Phase 3 | Unknown status | France | Colon Cancer Liver Metastasis | Infos |
| NCT02363049 | Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer | Interventional | Phase 3 | Unknown status | France | Malignant Neoplasm of Large Intestine | Infos |
| NCT02372500 | Trial of Chewing Gum to Reduce Post Operative Ileus in Elective Colorectal Surgery | Interventional | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT02379039 | Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer | Observational | N/A | Recruitment open | Sweden | Anal Cancer | Infos |
| NCT02384759 | Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers | Interventional | Phase 2 | Recruitment open | France | Colorectal Neoplasms | Infos |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Denmark | Gastric Cancer | Infos |
| NCT02395224 | A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway | Observational | N/A | Recruitment open | Norway | Neoplasm Metastasis | Infos |
| NCT02395224 | A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway | Observational | N/A | Recruitment open | Norway | Neoplasms, Colorectal | Infos |
| NCT02403050 | Feasibility Study of Fiducial Markers in Oesophageal Cancer | Observational | N/A | Unknown status | United Kingdom | Esophageal Neoplasms | Infos |
| NCT02404935 | Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) | Interventional | Phase 2 | Active but recruitment closed | France | Metastatic Colorectal Cancer | Infos |
| NCT02414009 | Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients | Interventional | Phase 2 | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT02416609 | Low-dose Radiotherapy Plus Chemotherapy With Gem-based Doublets and Stereotactic Radiotherapy for Advanced Pancreatic Cancer | Interventional | N/A | Recruitment open | Italy | Pancreatic Cancer | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Germany | Hepatocellular Carcinoma | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Germany | Pancreatic Cancer | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Poland | Hepatocellular Carcinoma | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Poland | Pancreatic Cancer | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Spain | Hepatocellular Carcinoma | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | Spain | Pancreatic Cancer | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02423239 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Interventional | Phase 1 | Unknown status | United Kingdom | Pancreatic Cancer | Infos |
| NCT02423785 | Ocular Blood Flow in Colorectal Cancer Patients | Observational | N/A | Recruitment open | Austria | Metastatic Colorectal Cancer | Infos |
| NCT02424279 | Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder | Interventional | N/A | Unknown status | Poland | Pain | Infos |
| NCT02424279 | Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder | Interventional | N/A | Unknown status | Poland | Pancreatic Cancer | Infos |
| NCT02425657 | Fast Track Module Based Colonoscopy Training Programme for Surgical Trainees at North Jutland Surgical Departments | Observational | N/A | Recruitment open | Denmark | Colorectal Cancer | Infos |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Interventional | Phase 3 | Recruitment open | Austria | Hepatocellular Carcinoma | Infos |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Interventional | Phase 3 | Recruitment open | Belgium | Hepatocellular Carcinoma | Infos |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Interventional | Phase 3 | Recruitment open | Czechia | Hepatocellular Carcinoma | Infos |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Interventional | Phase 3 | Recruitment open | France | Hepatocellular Carcinoma | Infos |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Interventional | Phase 3 | Recruitment open | Germany | Hepatocellular Carcinoma | Infos |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Interventional | Phase 3 | Recruitment open | Israel | Hepatocellular Carcinoma | Infos |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Interventional | Phase 3 | Recruitment open | Italy | Hepatocellular Carcinoma | Infos |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Interventional | Phase 3 | Recruitment open | Poland | Hepatocellular Carcinoma | Infos |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Interventional | Phase 3 | Recruitment open | Spain | Hepatocellular Carcinoma | Infos |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Interventional | Phase 3 | Recruitment open | Switzerland | Hepatocellular Carcinoma | Infos |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein | Interventional | Phase 3 | Recruitment open | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02436564 | In Vitro Models of Liver and Pancreatic Cancer | Observational | N/A | Unknown status | United Kingdom | Cholangiocarcinoma | Infos |
| NCT02436564 | In Vitro Models of Liver and Pancreatic Cancer | Observational | N/A | Unknown status | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02436564 | In Vitro Models of Liver and Pancreatic Cancer | Observational | N/A | Unknown status | United Kingdom | Pancreatic Neoplasm | Infos |
| NCT02443948 | Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST) | Observational | N/A | Unknown status | Italy | Gastrointestinal Stromal Tumor (GIST) | Infos |
| NCT02457156 | Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Pancreatic Cancer | Infos |
| NCT02458664 | BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer | Observational | N/A | Unknown status | France | Cancer of Colon | Infos |
| NCT02458664 | BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer | Observational | N/A | Unknown status | France | Rectum Cancer | Infos |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | Interventional | Phase 3 | Recruitment open | Belgium | Colon Cancer | Infos |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | Interventional | Phase 3 | Recruitment open | Germany | Colon Cancer | Infos |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | Interventional | Phase 3 | Recruitment open | Hungary | Colon Cancer | Infos |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | Interventional | Phase 3 | Recruitment open | Switzerland | Colon Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | Ovarian Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | Ovarian Neoplasm | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Israel | Ovarian Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Israel | Ovarian Neoplasm | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | Ovarian Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | Ovarian Neoplasm | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Ovarian Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Ovarian Neoplasm | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Ovarian Cancer | Infos |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Ovarian Neoplasm | Infos |
| NCT02476045 | Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino) | Interventional | Phase 2 | Unknown status | Italy | Metastatic Colorectal Cancer | Infos |
| NCT02489058 | A Study of Long-Term Responders on Olaparib | Observational | N/A | Recruitment open | Italy | Peritoneal Cancer | Infos |
| NCT02489058 | A Study of Long-Term Responders on Olaparib | Observational | N/A | Recruitment open | Spain | Peritoneal Cancer | Infos |
| NCT02489058 | A Study of Long-Term Responders on Olaparib | Observational | N/A | Recruitment open | United Kingdom | Peritoneal Cancer | Infos |
| NCT02494973 | Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases | Interventional | Phase 2/Phase 3 | Recruitment open | France | Colorectal Cancer | Infos |
| NCT02497820 | Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers | Interventional | Phase 3 | Not yet recruiting | Israel | Lynch Syndrome I (Site-specific Colonic Cancer) | Infos |
| NCT02502656 | RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | France | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Germany | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Italy | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Spain | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Switzerland | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma (HCC) | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Belgium | Gastrointestinal Stromal Tumors (GIST) | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Belgium | Other Relapsed or Refractory Solid Tumors | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | France | Gastrointestinal Stromal Tumors (GIST) | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | France | Other Relapsed or Refractory Solid Tumors | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Germany | Gastrointestinal Stromal Tumors (GIST) | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Germany | Other Relapsed or Refractory Solid Tumors | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Italy | Gastrointestinal Stromal Tumors (GIST) | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Italy | Other Relapsed or Refractory Solid Tumors | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Netherlands | Gastrointestinal Stromal Tumors (GIST) | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Netherlands | Other Relapsed or Refractory Solid Tumors | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Poland | Gastrointestinal Stromal Tumors (GIST) | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Poland | Other Relapsed or Refractory Solid Tumors | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Spain | Gastrointestinal Stromal Tumors (GIST) | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Spain | Other Relapsed or Refractory Solid Tumors | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Gastrointestinal Stromal Tumors (GIST) | Infos |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Other Relapsed or Refractory Solid Tumors | Infos |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 | Interventional | Phase 1/Phase 2 | Recruitment open | Austria | Hepatocellular Carcinoma | Infos |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 | Interventional | Phase 1/Phase 2 | Recruitment open | Belgium | Hepatocellular Carcinoma | Infos |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 | Interventional | Phase 1/Phase 2 | Recruitment open | Germany | Hepatocellular Carcinoma | Infos |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 | Interventional | Phase 1/Phase 2 | Recruitment open | Poland | Hepatocellular Carcinoma | Infos |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 | Interventional | Phase 1/Phase 2 | Recruitment open | Spain | Hepatocellular Carcinoma | Infos |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 | Interventional | Phase 1/Phase 2 | Recruitment open | Switzerland | Hepatocellular Carcinoma | Infos |
| NCT02510001 | MEK and MET Inhibition in Colorectal Cancer | Interventional | Phase 1 | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT02510001 | MEK and MET Inhibition in Colorectal Cancer | Interventional | Phase 1 | Unknown status | United Kingdom | Solid Tumor | Infos |
| NCT02511223 | Efficacy and Safety of PARPi to Treat Pancreatic Cancer | Interventional | Phase 2 | Unknown status | Israel | Pancreatic Cancer | Infos |
| NCT02512263 | Assessment of Adherence and Efficiency of a Home-based Training Program on Muscular Strength, Endurance and Qol for Colon Cancer Patients | Interventional | N/A | Unknown status | Belgium | Colon Cancer | Infos |
| NCT02513849 | Tamoxifen in Patients With Oesophageal Cancer | Interventional | Phase 1 | Unknown status | United Kingdom | Cancer | Infos |
| NCT02513849 | Tamoxifen in Patients With Oesophageal Cancer | Interventional | Phase 1 | Unknown status | United Kingdom | Gastrointestinal Neoplasms | Infos |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | Interventional | Phase 2 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | Interventional | Phase 2 | Active but recruitment closed | Spain | Hepatocellular Carcinoma | Infos |
| NCT02519582 | Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy | Interventional | Phase 2 | Unknown status | Germany | Colorectal Cancer | Infos |
| NCT02522520 | Pedometer Intervention and Health Effects for Sedentary Colorectal Cancer Patients During Adjuvant Chemotherapy | Interventional | N/A | Active but recruitment closed | Denmark | Colorectal Cancer | Infos |
| NCT02526264 | Evaluation of Quality of Life and Period of Hospitalization by Education | Interventional | N/A | Recruitment open | Germany | Colorectal Cancer | Infos |
| NCT02526836 | Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer | Interventional | Phase 2/Phase 3 | Unknown status | Italy | Colon Cancer | Infos |
| NCT02530593 | QoLiCOL - Quality of Life in Colon Cancer | Observational | N/A | Active but recruitment closed | Sweden | Colonic Neoplasm | Infos |
| NCT02539537 | A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma | Interventional | Phase 3 | Recruitment open | France | Pancreatic Cancer | Infos |
| NCT02545699 | Prospective Trial to Compare ADR of G-EYE™ Colonoscopy With Standard Colonoscopy | Interventional | N/A | Unknown status | Israel | Colorectal Cancer | Infos |
| NCT02546973 | Quality of Life in Patients With Anal Cancer | Observational | N/A | Active but recruitment closed | Sweden | Anal Cancer | Infos |
| NCT02551458 | Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy | Interventional | Phase 2/Phase 3 | Recruitment open | France | Adenocarcinoma of the Oesogastric Junction (Siewert Type I or II) | Infos |
| NCT02551458 | Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy | Interventional | Phase 2/Phase 3 | Recruitment open | France | Adenocarcinoma of the Thoracic Oesophagus or | Infos |
| NCT02551458 | Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy | Interventional | Phase 2/Phase 3 | Recruitment open | France | Epidermoid Carcinoma or | Infos |
| NCT02551458 | Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy | Interventional | Phase 2/Phase 3 | Recruitment open | France | Stage cT2 N1-3 M0 or cT3-T4a N0 or N1-3 M0 | Infos |
| NCT02551991 | Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Pancreatic Cancer | Infos |
| NCT02556281 | Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III | Interventional | N/A | Unknown status | France | Colorectal Neoplasms | Infos |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine | Interventional | Phase 2 | Recruitment open | Germany | Adenocarcinoma of the Pancreas | Infos |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine | Interventional | Phase 2 | Recruitment open | Germany | Metastatic Pancreatic Cancer | Infos |
| NCT02567253 | Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer | Interventional | Phase 2 | Recruitment open | Belgium | Primary Peritoneal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Belgium | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Belgium | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | France | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | France | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Germany | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Germany | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Italy | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Italy | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Netherlands | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Netherlands | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Poland | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Poland | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Spain | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | Spain | Pancreatic Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | United Kingdom | Colorectal Cancer | Infos |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Interventional | Phase 2 | Recruitment open | United Kingdom | Pancreatic Cancer | Infos |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | Interventional | Phase 1 | Recruitment open | Austria | Gastrointestinal Stromal Tumors | Infos |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | Interventional | Phase 1 | Recruitment open | Germany | Gastrointestinal Stromal Tumors | Infos |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | Interventional | Phase 1 | Recruitment open | Italy | Gastrointestinal Stromal Tumors | Infos |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | Interventional | Phase 1 | Recruitment open | Netherlands | Gastrointestinal Stromal Tumors | Infos |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | Interventional | Phase 1 | Recruitment open | Spain | Gastrointestinal Stromal Tumors | Infos |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | Interventional | Phase 1 | Recruitment open | United Kingdom | Gastrointestinal Stromal Tumors | Infos |
| NCT02574013 | Randomized Controlled Trial for Retractor SPONGE Evaluation in Laparoscopic Colorectal Surgery | Interventional | N/A | Recruitment open | Netherlands | Colorectal Cancer | Infos |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Romania | HCC | Infos |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Romania | Hepatocellular Carcinoma | Infos |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Romania | Liver Cancer | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Belgium | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Czechia | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Denmark | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | France | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Germany | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Greece | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Hungary | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Ireland | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Italy | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Norway | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Poland | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Portugal | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Russian Federation | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Slovakia | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Spain | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Sweden | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | Turkey | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576431 | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Interventional | Phase 2 | Recruitment open | United Kingdom | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Austria | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Belgium | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Czechia | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Germany | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Israel | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Poland | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Spain | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Sweden | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | Switzerland | Hepatocellular Carcinoma | Infos |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02577627 | Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC | Observational | N/A | Unknown status | Israel | Colon Cancer | Infos |
| NCT02578368 | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | Interventional | Phase 3 | Recruitment open | Germany | Gastric Cancer | Infos |
| NCT02591667 | Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer | Interventional | Phase 2 | Unknown status | Austria | Colorectal Cancer | Infos |
| NCT02591667 | Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer | Interventional | Phase 2 | Unknown status | Austria | Peritoneal Metastasis | Infos |
| NCT02597075 | Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy | Interventional | N/A | Active but recruitment closed | Austria | Metastatic Colorectal Cancer | Infos |
| NCT02597075 | Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy | Interventional | N/A | Active but recruitment closed | Switzerland | Metastatic Colorectal Cancer | Infos |
| NCT02597348 | Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy | Interventional | Phase 3 | Recruitment open | France | Colorectal Cancer | Infos |
| NCT02606305 | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Belgium | Primary Peritoneal Cancer | Infos |
| NCT02606305 | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Primary Peritoneal Cancer | Infos |
| NCT02614534 | Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma | Interventional | Phase 3 | Recruitment open | Spain | Colorectal Cancer | Infos |
| NCT02618850 | PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment | Interventional | N/A | Active but recruitment closed | Italy | Colorectal Cancer Stage IV | Infos |
| NCT02619435 | Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Italy | Advanced Colorectal Cancer | Infos |
| NCT02624271 | Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk | Interventional | N/A | Unknown status | France | Gastric Cancer | Infos |
| NCT02624271 | Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk | Interventional | N/A | Unknown status | France | Gastric Precancerous Lesions | Infos |
| NCT02624726 | Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment | Interventional | Phase 2 | Unknown status | Greece | Metastatic Colorectal Cancer | Infos |
| NCT02625610 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | Interventional | Phase 3 | Active but recruitment closed | France | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Infos |
| NCT02625610 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | Interventional | Phase 3 | Active but recruitment closed | Germany | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Infos |
| NCT02625610 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Infos |
| NCT02625610 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | Interventional | Phase 3 | Active but recruitment closed | Italy | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Infos |
| NCT02625610 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | Interventional | Phase 3 | Active but recruitment closed | Romania | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Infos |
| NCT02625610 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Infos |
| NCT02625610 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | Interventional | Phase 3 | Active but recruitment closed | Spain | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Infos |
| NCT02625610 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | Interventional | Phase 3 | Active but recruitment closed | Turkey | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Infos |
| NCT02625610 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction | Infos |
| NCT02626377 | Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté | Interventional | N/A | Recruitment open | France | Colorectal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Denmark | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | France | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Germany | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Israel | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Italy | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Netherlands | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Norway | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Russian Federation | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | Spain | Anal Cancer | Infos |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Interventional | Phase 2 | Recruitment open | United Kingdom | Anal Cancer | Infos |
| NCT02633098 | A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer | Interventional | Phase 2 | Recruitment open | United Kingdom | Bowel Cancer | Infos |
| NCT02633098 | A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer | Interventional | Phase 2 | Recruitment open | United Kingdom | Colorectal Cancer | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Czechia | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Denmark | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | France | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Germany | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Ireland | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Israel | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Italy | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Netherlands | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Poland | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Russian Federation | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Spain | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Sweden | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Switzerland | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Turkey | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | Ukraine | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children | Interventional | Phase 1/Phase 2 | Recruitment open | United Kingdom | Solid Tumors Harboring NTRK Fusion | Infos |
| NCT02638766 | Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST | Interventional | Phase 2 | Recruitment open | France | Gastrointestinal Stromal Tumors | Infos |
| NCT02638766 | Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST | Interventional | Phase 2 | Recruitment open | Italy | Gastrointestinal Stromal Tumors | Infos |
| NCT02638766 | Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST | Interventional | Phase 2 | Recruitment open | Spain | Gastrointestinal Stromal Tumors | Infos |
| NCT02646462 | Systematic Lymph Node Sampling and Analysis in Patients With Pancreatic Cancer | Observational | N/A | Unknown status | Denmark | Pancreatic Cancer | Infos |
| NCT02647099 | Adjuvant Low Dose Aspirin in Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Denmark | Colorectal Cancer | Infos |
| NCT02647099 | Adjuvant Low Dose Aspirin in Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Finland | Colorectal Cancer | Infos |
| NCT02647099 | Adjuvant Low Dose Aspirin in Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Norway | Colorectal Cancer | Infos |
| NCT02647099 | Adjuvant Low Dose Aspirin in Colorectal Cancer | Interventional | Phase 3 | Recruitment open | Sweden | Colorectal Cancer | Infos |
| NCT02665312 | Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine | Observational | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT02668913 | LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer | Interventional | Phase 1/Phase 2 | Unknown status | United Kingdom | Peritoneal Cancer | Infos |
| NCT02672774 | Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers | Interventional | N/A | Unknown status | Romania | Colorectal Cancer | Infos |
| NCT02672774 | Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers | Interventional | N/A | Unknown status | Romania | Gastric Cancer | Infos |
| NCT02672774 | Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers | Interventional | N/A | Unknown status | Romania | Gastrointestinal Neoplasms | Infos |
| NCT02674100 | American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry | Observational | N/A | Recruitment open | United Kingdom | Pancreatic Cancer | Infos |
| NCT02674373 | Prognostic and Predictive Impact of Circulating Tumor DNA in Gastric Cancer Treatment | Observational | N/A | Unknown status | France | Gastric Cancer | Infos |
| NCT02678182 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | Interventional | Phase 2 | Recruitment open | United Kingdom | Adenocarcinoma of the Gastro-oesophageal Junction | Infos |
| NCT02678182 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | Interventional | Phase 2 | Recruitment open | United Kingdom | Adenocarcinoma of the Oesophagus | Infos |
| NCT02678182 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | Interventional | Phase 2 | Recruitment open | United Kingdom | Adenocarcinoma of the Stomach | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Czechia | Ovarian Neoplasms | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Hungary | Ovarian Neoplasms | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Poland | Ovarian Neoplasms | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Slovakia | Ovarian Neoplasms | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Spain | Ovarian Neoplasms | Infos |
| NCT02687321 | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Observational | N/A | Unknown status | Ukraine | Ovarian Neoplasms | Infos |
| NCT02697084 | Individual Following in Anal Cancer With PET/CT | Observational | N/A | Recruitment open | France | Anal Cancer | Infos |
| NCT02701088 | Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life | Interventional | Phase 2 | Recruitment open | France | Locally Advanced Anal Canal Cancer | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | Belgium | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | Denmark | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | Germany | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | Hungary | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | Ireland | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | Israel | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | Norway | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | Poland | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | Turkey | Hepatocellular Carcinoma | Infos |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | Belgium | Hepatocellular Carcinoma | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | Germany | Hepatocellular Carcinoma | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | Sweden | Hepatocellular Carcinoma | Infos |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | Interventional | Phase 2 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02702986 | Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC) | Interventional | Phase 1 | Active but recruitment closed | Italy | Pancreatic Cancer | Infos |
| NCT02704832 | Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE) | Interventional | Phase 3 | Recruitment open | France | Colorectal Cancer | Infos |
| NCT02705300 | Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer | Interventional | Phase 2 | Active but recruitment closed | Denmark | Colorectal Cancer | Infos |
| NCT02707159 | Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients | Interventional | Phase 2 | Unknown status | Norway | Metastatic Pancreatic Cancer | Infos |
| NCT02707796 | Correlation Between Partial Oxygen Pressure and Oxygen Reserve Index | Interventional | N/A | Unknown status | Turkey | COLON CANCER | Infos |
| NCT02715141 | Molecular Stool Testing for Colorectal Cancer Surveillance | Observational | N/A | Unknown status | Netherlands | Colorectal Cancer | Infos |
| NCT02715882 | Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer | Interventional | Phase 2 | Unknown status | Russian Federation | Colorectal Cancer | Infos |
| NCT02716012 | First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02716012 | First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Liver Cancer | Infos |
| NCT02721056 | NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Liver Cancer | Infos |
| NCT02726243 | Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT02726243 | Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease | Observational | N/A | Unknown status | France | Inflammatory Bowel Disease | Infos |
| NCT02732301 | Postoperative Gastrointestinal Dysfunction After Cardiac Surgery - Occurrence and Search for Biomarkers | Observational | N/A | Active but recruitment closed | Sweden | Gastrointestinal Tract | Infos |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Gastric Cancers | Infos |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Israel | Gastric Cancers | Infos |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Gastric Cancers | Infos |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Switzerland | Gastric Cancers | Infos |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Gastric Cancers | Infos |
| NCT02735239 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | Interventional | Phase 1/Phase 2 | Active but recruitment closed | United Kingdom | Esophageal Cancer | Infos |
| NCT02738359 | Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening | Observational | N/A | Recruitment open | France | Colon Cancer | Infos |
| NCT02738359 | Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening | Observational | N/A | Recruitment open | France | Rectum Cancer | Infos |
| NCT02741167 | Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | Observational | N/A | Unknown status | Switzerland | Peritoneal Cancer | Infos |
| NCT02741856 | Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation | Interventional | Phase 2/Phase 3 | Recruitment open | United Kingdom | Oesophageal Cancer | Infos |
| NCT02745600 | Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment | Interventional | N/A | Unknown status | Austria | Hepatocellular Carcinoma | Infos |
| NCT02745600 | Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment | Interventional | N/A | Unknown status | Finland | Hepatocellular Carcinoma | Infos |
| NCT02745600 | Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment | Interventional | N/A | Unknown status | Germany | Hepatocellular Carcinoma | Infos |
| NCT02745600 | Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment | Interventional | N/A | Unknown status | Netherlands | Hepatocellular Carcinoma | Infos |
| NCT02746224 | Reconstruction Techniques and Vascular Approach After Laparoscopic Left Hemicolectomy and Rectum Low Anterior Resection | Interventional | N/A | Recruitment open | Spain | Colorectal Cancer | Infos |
| NCT02748551 | A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric Cancer | Interventional | Phase 3 | Recruitment open | Russian Federation | Gastric Cancer | Infos |
| NCT02748551 | A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric Cancer | Interventional | Phase 3 | Recruitment open | Ukraine | Gastric Cancer | Infos |
| NCT02751086 | Robotic, Laparoscopic and Open Gastrectomy Compared on Short and Long Term Outcomes | Observational | N/A | Recruitment open | Italy | Gastric Cancer | Infos |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Belgium | Colorectal Cancer | Infos |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Czechia | Colorectal Cancer | Infos |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Israel | Colorectal Cancer | Infos |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Italy | Colorectal Cancer | Infos |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | Colorectal Cancer | Infos |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Colorectal Cancer | Infos |
| NCT02756455 | Procalcitonin Reveals Early Dehiscence in Gastric Surgery: the PREDIGS Study | Observational | N/A | Unknown status | Italy | Gastric Cancer | Infos |
| NCT02756468 | Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study | Observational | N/A | Unknown status | Italy | Pancreatic Cancer | Infos |
| NCT02758951 | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | Interventional | Phase 2/Phase 3 | Recruitment open | Netherlands | Colorectal Cancer | Infos |
| NCT02758951 | Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases | Interventional | Phase 2/Phase 3 | Recruitment open | Netherlands | Peritoneal Cancer | Infos |
| NCT02758977 | Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM) | Interventional | N/A | Unknown status | Switzerland | Colon Cancer Liver Metastases | Infos |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC) | Interventional | Phase 1/Phase 2 | Unknown status | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02767557 | Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients | Interventional | Phase 2 | Recruitment open | Denmark | Unresectable Pancreatic Carcinoma | Infos |
| NCT02767557 | Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients | Interventional | Phase 2 | Recruitment open | Norway | Unresectable Pancreatic Carcinoma | Infos |
| NCT02780921 | Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial | Interventional | Phase 3 | Unknown status | France | Gastric Cancer | Infos |
| NCT02780921 | Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial | Interventional | Phase 3 | Unknown status | France | Oesophageal Cancer | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Recruitment open | Austria | Colon Cancer Liver Metastasis | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Recruitment open | Austria | Colorectal Cancer | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Recruitment open | Belgium | Colon Cancer Liver Metastasis | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Recruitment open | Belgium | Colorectal Cancer | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Recruitment open | France | Colon Cancer Liver Metastasis | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Recruitment open | France | Colorectal Cancer | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Recruitment open | Poland | Colon Cancer Liver Metastasis | Infos |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis | Observational | N/A | Recruitment open | Poland | Colorectal Cancer | Infos |
| NCT02785263 | Shared Decision Making With Anal Cancer Patients on Radiation Dose | Interventional | N/A | Recruitment open | Denmark | Anal Cancer | Infos |
| NCT02785835 | Hepatocellular Carcinoma in HIV-infected Patients | Observational | N/A | Recruitment open | Spain | Chronic Hepatitis C | Infos |
| NCT02785835 | Hepatocellular Carcinoma in HIV-infected Patients | Observational | N/A | Recruitment open | Spain | Hepatitis B Virus | Infos |
| NCT02785835 | Hepatocellular Carcinoma in HIV-infected Patients | Observational | N/A | Recruitment open | Spain | Hepatocellular Carcinoma | Infos |
| NCT02785835 | Hepatocellular Carcinoma in HIV-infected Patients | Observational | N/A | Recruitment open | Spain | HIV | Infos |
| NCT02785835 | Hepatocellular Carcinoma in HIV-infected Patients | Observational | N/A | Recruitment open | Spain | Liver Cirrhosis | Infos |
| NCT02786329 | Anesthesia and Postoperative Outcome in Colorectal Cancer Patients | Interventional | Early Phase 1 | Recruitment open | Romania | Colorectal Cancer | Infos |
| NCT02786342 | Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib | Observational | N/A | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT02788669 | LRP1 and Colon Cancer | Observational | N/A | Unknown status | France | Adenocarcinoma | Infos |
| NCT02788669 | LRP1 and Colon Cancer | Observational | N/A | Unknown status | France | Colon Cancer | Infos |
| NCT02789709 | Metabolomic Phenotyping After Surgery for Colon Cancer: Study of Novel Predictive Biomarkers | Observational | N/A | Unknown status | Spain | Colon Cancer | Infos |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Belgium | Pancreatic Cancer | Infos |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | France | Pancreatic Cancer | Infos |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Israel | Pancreatic Cancer | Infos |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Netherlands | Pancreatic Cancer | Infos |
| NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | Interventional | Phase 1 | Active but recruitment closed | Spain | Pancreatic Cancer | Infos |
| NCT02792023 | Usefulness of Fecal Immunochemical Test in Iron Deficiency Anemia (IDAFIT) | Interventional | N/A | Recruitment open | Spain | Colorectal Cancer | Infos |
| NCT02795429 | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | Interventional | Phase 1/Phase 2 | Active but recruitment closed | France | Advanced Hepatocellular Carcinoma | Infos |
| NCT02795429 | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Germany | Advanced Hepatocellular Carcinoma | Infos |
| NCT02795429 | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Advanced Hepatocellular Carcinoma | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | Georgia | Adenocarcinoma | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | Georgia | Gastrointestinal Neoplasms | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | Serbia | Adenocarcinoma | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | Serbia | Gastrointestinal Neoplasms | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | Ukraine | Adenocarcinoma | Infos |
| NCT02795988 | A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Interventional | Phase 1/Phase 2 | Recruitment open | Ukraine | Gastrointestinal Neoplasms | Infos |
| NCT02798003 | Food Reward in Cachexia Induced by Acute or Chronic Disease | Observational | N/A | Unknown status | Netherlands | Pancreatic Cancer | Infos |
| NCT02799212 | Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma | Interventional | Phase 3 | Recruitment open | France | Hepatocellular Carcinoma | Infos |
| NCT02804802 | Impact of DietarY and LIfestyle Risk Factors on Colorectal Cancer Screening | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | Interventional | Phase 3 | Recruitment open | Ireland | Colorectal Cancer | Infos |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | Interventional | Phase 3 | Recruitment open | Ireland | Gastro-oesophageal Cancer | Infos |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | Interventional | Phase 3 | Recruitment open | United Kingdom | Colorectal Cancer | Infos |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | Interventional | Phase 3 | Recruitment open | United Kingdom | Gastro-oesophageal Cancer | Infos |
| NCT02806687 | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer | Interventional | Phase 2 | Recruitment open | France | Pancreatic Adenocarcinoma | Infos |
| NCT02811666 | Impact of Preoperative Sarcopenia on Morbidity and Mortality in Patients Operated on From Digestive Cancers | Interventional | N/A | Unknown status | France | Liver Cancer | Infos |
| NCT02811666 | Impact of Preoperative Sarcopenia on Morbidity and Mortality in Patients Operated on From Digestive Cancers | Interventional | N/A | Unknown status | France | Pancreatic Cancer | Infos |
| NCT02812992 | Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients | Interventional | Phase 4 | Active but recruitment closed | Germany | Adenocarcinoma Pancreas | Infos |
| NCT02813824 | Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome | Interventional | Phase 3 | Recruitment open | France | Lynch Syndrome | Infos |
| NCT02813928 | Diagnostic and Prognosis Value of Circulating DNA for CRC Patients' Surveillance After Curative Treatment | Interventional | N/A | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT02817178 | Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer | Interventional | N/A | Unknown status | France | Metastatic Colorectal Cancer | Infos |
| NCT02818907 | Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable | Interventional | N/A | Recruitment open | France | Pancreatic Cancer | Infos |
| NCT02820389 | CT Colonography as the Initial Diagnostic Imaging Tool for Patients With Suspected Colorectal Cancer | Observational | N/A | Unknown status | United Kingdom | Colorectal Cancer | Infos |
| NCT02821793 | Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer | Observational | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT02824185 | Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma | Interventional | N/A | Recruitment open | France | Patients Eligible to a Curative Treatment for Primary HCC | Infos |
| NCT02824484 | A Guided Written Disclosure Intervention to Promote Post-traumatic Growth in Cancer Patients GUIDED WRITTEN DISCLOSURE | Interventional | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT02826486 | Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) | Interventional | Phase 2 | Active but recruitment closed | Israel | Metastatic Pancreatic Adenocarcinoma | Infos |
| NCT02826486 | Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) | Interventional | Phase 2 | Active but recruitment closed | Spain | Metastatic Pancreatic Adenocarcinoma | Infos |
| NCT02827201 | FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine | Interventional | Phase 2 | Active but recruitment closed | France | Metastatic Pancreatic Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Belgium | Advanced Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Belgium | Hepatic Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Belgium | Hepatic Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Belgium | Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Belgium | Liver Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Belgium | Liver Neoplasms | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | France | Advanced Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | France | Hepatic Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | France | Hepatic Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | France | Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | France | Liver Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | France | Liver Neoplasms | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Italy | Advanced Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Italy | Hepatic Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Italy | Hepatic Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Italy | Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Italy | Liver Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Italy | Liver Neoplasms | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Russian Federation | Advanced Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Russian Federation | Hepatic Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Russian Federation | Hepatic Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Russian Federation | Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Russian Federation | Liver Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Russian Federation | Liver Neoplasms | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Spain | Advanced Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Spain | Hepatic Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Spain | Hepatic Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Spain | Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Spain | Liver Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | Spain | Liver Neoplasms | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Advanced Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Hepatic Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Hepatic Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Liver Cancer | Infos |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | Interventional | Phase 1 | Active but recruitment closed | United Kingdom | Liver Neoplasms | Infos |
| NCT02841657 | 3D Laparoscopy Versus 2D Laparoscopy | Observational | N/A | Unknown status | Italy | Colorectal Cancer | Infos |
| NCT02842294 | Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer | Observational | N/A | Unknown status | France | Metastatic Colorectal Cancer | Infos |
| NCT02842294 | Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer | Observational | N/A | Unknown status | France | Quality of Life | Infos |
| NCT02844608 | Feasibility of Quality of Life Assessment in Routine Clinical Oncology Practice at the University Hospital of Besancon | Interventional | N/A | Unknown status | France | Colorectal Cancer | Infos |
| NCT02847468 | Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib | Interventional | N/A | Recruitment open | France | Carcinoma, Hepatocellular | Infos |
| NCT02848807 | Chemotherapy-related Toxicity, Nutritional Status and Quality of Life | Interventional | N/A | Unknown status | Poland | Metastatic Colorectal Cancer | Infos |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy | Interventional | Phase 3 | Recruitment open | France | Bile Duct Cancer | Infos |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy | Interventional | Phase 3 | Recruitment open | France | Esophageal Cancer | Infos |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy | Interventional | Phase 3 | Recruitment open | France | Gastric Cancer | Infos |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy | Interventional | Phase 3 | Recruitment open | France | Gastroesophageal Cancer | Infos |
| NCT02853474 | Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy | Interventional | Phase 3 | Recruitment open | France | Pancreas Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Czechia | Epithelial Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Czechia | Fallopian Tube Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Czechia | Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Czechia | Peritoneal Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Hungary | Epithelial Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Hungary | Fallopian Tube Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Hungary | Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Hungary | Peritoneal Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Israel | Epithelial Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Israel | Fallopian Tube Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Israel | Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Israel | Peritoneal Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Italy | Epithelial Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Italy | Fallopian Tube Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Italy | Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Italy | Peritoneal Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Poland | Epithelial Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Poland | Fallopian Tube Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Poland | Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Poland | Peritoneal Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Epithelial Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Fallopian Tube Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Peritoneal Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Spain | Epithelial Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Spain | Fallopian Tube Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Spain | Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Spain | Peritoneal Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Ukraine | Epithelial Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Ukraine | Fallopian Tube Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Ukraine | Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | Ukraine | Peritoneal Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Epithelial Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Fallopian Tube Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Ovarian Cancer | Infos |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Peritoneal Cancer | Infos |
| NCT02857270 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Interventional | Phase 1 | Active but recruitment closed | France | Colorectal Cancer | Infos |
| NCT02857270 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Interventional | Phase 1 | Active but recruitment closed | Germany | Colorectal Cancer | Infos |
| NCT02858141 | Onco-geriatric Database of Patients With Pancreatic Cancer | Observational | N/A | Unknown status | France | Pancreatic Neoplasms | Infos |
| NCT02859753 | Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency Ablation | Interventional | N/A | Unknown status | France | Hepatocellular Carcinoma | Infos |
| NCT02861209 | Collaborative Network to Take Responsibility for Oral Anticancer Therapy | Interventional | N/A | Recruitment open | Belgium | Colorectal Cancer | Infos |
| NCT02861430 | Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular Biology | Observational | N/A | Unknown status | France | Colon Cancer | Infos |
| NCT02861430 | Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular Biology | Observational | N/A | Unknown status | France | Lymph Node | Infos |
| NCT02861430 | Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular Biology | Observational | N/A | Unknown status | France | Sentinel Node | Infos |
| NCT02866383 | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients | Interventional | Phase 2 | Recruitment open | Denmark | Metastatic Biliary Tract Cancer | Infos |
| NCT02866383 | Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients | Interventional | Phase 2 | Recruitment open | Denmark | Metastatic Pancreatic Cancer | Infos |
| NCT02869503 | Institut Paoli Calmettes Colorectal Cancer Database | Observational | N/A | Recruitment open | France | Colorectal Neoplasms | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Czechia | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | France | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Germany | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Greece | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Hungary | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Israel | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Italy | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Portugal | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Romania | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | Turkey | Gastric Cancer | Infos |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | Gastric Cancer | Infos |
| NCT02872779 | Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer | Interventional | N/A | Unknown status | France | Circulating Markers | Infos |
| NCT02872779 | Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer | Interventional | N/A | Unknown status | France | Metastatic Colorectal Cancer | Infos |
| NCT02873845 | Role of the Spouse/Partner of Persons Treated With Chemotherapy for Colon Cancer | Observational | N/A | Unknown status | France | Colon Cancer | Infos |
| NCT02876133 | Narrow Band Imaging Versus White Light for Colonoscopy Serrate Lesions Detection | Interventional | N/A | Unknown status | Portugal | Colon Cancer | Infos |
| NCT02884453 | Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma | Interventional | Phase 2 | Recruitment open | United Kingdom | Gastrooesophageal Cancer | Infos |
| NCT02885142 | Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery? | Interventional | N/A | Unknown status | France | Anal Cancer | Infos |
| NCT02885753 | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver | Interventional | Phase 3 | Recruitment open | France | Colorectal Neoplasms | Infos |
| NCT02890069 | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Interventional | Phase 1 | Recruitment open | Germany | Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma | Infos |
| NCT02890069 | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Interventional | Phase 1 | Recruitment open | Netherlands | Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma | Infos |
| NCT02890069 | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Interventional | Phase 1 | Recruitment open | Spain | Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma | Infos |
| NCT02890069 | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Interventional | Phase 1 | Recruitment open | United Kingdom | Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma | Infos |
| NCT02900664 | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | Interventional | Phase 1 | Active but recruitment closed | Belgium | Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma | Infos |
| NCT02900664 | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | Interventional | Phase 1 | Active but recruitment closed | France | Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma | Infos |
| NCT02900664 | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | Interventional | Phase 1 | Active but recruitment closed | Israel | Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma | Infos |
| NCT02900664 | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | Interventional | Phase 1 | Active but recruitment closed | Italy | Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma | Infos |
| NCT02900664 | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | Interventional | Phase 1 | Active but recruitment closed | Spain | Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma | Infos |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Colorectal Cancer (CRC) | Infos |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Italy | Gastric Cancer | Infos |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Colorectal Cancer (CRC) | Infos |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Netherlands | Gastric Cancer | Infos |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Colorectal Cancer (CRC) | Infos |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | Interventional | Phase 1/Phase 2 | Active but recruitment closed | Spain | Gastric Cancer | Infos |
| NCT02904031 | Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients | Interventional | Phase 2 | Active but recruitment closed | Italy | Elderly Metastatic Colorectal Cancer Patients | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion | Interventional | Phase 1/Phase 2 | Recruitment open | France | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion | Interventional | Phase 1/Phase 2 | Recruitment open | Israel | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion | Interventional | Phase 1/Phase 2 | Recruitment open | Italy | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion | Interventional | Phase 1/Phase 2 | Recruitment open | Netherlands | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion | Interventional | Phase 1/Phase 2 | Recruitment open | Norway | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion | Interventional | Phase 1/Phase 2 | Recruitment open | Portugal | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion | Interventional | Phase 1/Phase 2 | Recruitment open | Spain | Pancreatic Cancer Harboring NRG1 Fusion | Infos |
| NCT02919644 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. | Interventional | Phase 2 | Recruitment open | Italy | Curative Resection | Infos |
| NCT02919644 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. | Interventional | Phase 2 | Recruitment open | Italy | Stage IV Colorectal Cancer | Infos |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | Interventional | Phase 2/Phase 3 | Recruitment open | Denmark | Pancreatic Cancer | Infos |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | Interventional | Phase 2/Phase 3 | Recruitment open | Finland | Pancreatic Cancer | Infos |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | Interventional | Phase 2/Phase 3 | Recruitment open | Norway | Pancreatic Cancer | Infos |
| NCT02919787 | Nordic Pancreatic Cancer Trial (NorPACT) - 1 | Interventional | Phase 2/Phase 3 | Recruitment open | Sweden | Pancreatic Cancer | Infos |
| NCT02924714 | SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST | Interventional | N/A | Recruitment open | Norway | Gastrointestinal Stromal Tumor | Infos |
| NCT02928120 | Diagnostic Potential of Hypermethylated DNA in Colorectal Cancer | Observational | N/A | Unknown status | Denmark | Aberrant DNA Methylation | Infos |
| NCT02928120 | Diagnostic Potential of Hypermethylated DNA in Colorectal Cancer | Observational | N/A | Unknown status | Denmark | Colorectal Neoplasms | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Austria | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Belgium | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Czechia | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Denmark | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | France | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Germany | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Hungary | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Israel | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Italy | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Netherlands | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Norway | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Poland | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Russian Federation | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Spain | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Turkey | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | Ukraine | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928224 | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Interventional | Phase 3 | Active but recruitment closed | United Kingdom | BRAF V600E-mutant Metastatic Colorectal Cancer | Infos |
| NCT02928627 | Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in Hepatocellular Carcinoma | Observational | N/A | Unknown status | United Kingdom | Hepatocellular Carcinoma | Infos |
| NCT02931890 | Multicentric Randomised Trial for Resectable Gastric Cancer | Interventional | Phase 2 | Recruitment open | Netherlands | Gastric Cancer | Infos |
| NCT02934529 | Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | Interventional | Phase 3 | Recruitment open | Germany | Metastatic Colorectal Cancer | Infos |
| NCT02935634 | A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer | Interventional | Phase 2 | Recruitment open | France | Advanced Gastric Cancer | Infos |
| NCT02935634 | A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer | Interventional | Phase 2 | Recruitment open | Germany | Advanced Gastric Cancer | Infos |
| NCT02935634 | A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer | Interventional | Phase 2 | Recruitment open | Israel | Advanced Gastric Cancer | Infos |
| NCT02935634 | A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer | Interventional | Phase 2 | Recruitment open | Italy | Advanced Gastric Cancer | Infos |
| NCT02935634 | A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer | Interventional | Phase 2 | Recruitment open | Netherlands | Advanced Gastric Cancer | Infos |
| NCT02935634 | A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer | Interventional | Phase 2 | Recruitment open | Spain | Advanced Gastric Cancer | Infos |
| NCT02935634 | A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer | Interventional | Phase 2 | Recruitment open | Switzerland | Advanced Gastric Cancer | Infos |
| NCT02938481 | International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer | Observational | N/A | Active but recruitment closed | Germany | Colon Cancer | Infos |
| NCT02938481 | International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer | Observational | N/A | Active but recruitment closed | Lithuania | Colon Cancer | Infos |
| NCT02938481 | International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer | Observational | N/A | Active but recruitment closed | Russian Federation | Colon Cancer |